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7.2.1.3	Thy1.1+	Clone	4	T	Cells	cannot	be	expanded	 from	the	Spleens	of	 tumour	bearing	mice	 in	ex	vivo	
culture	.......................................................................................................................................................................................................	261 





















































































































































































































hCD2	 human	CD2	 	 	

















































































































harm	 to	 the	body	 are	known	as	pathogens.	 In	 addition,	 the	 immune	 system	can	detect	 and	
respond	to	tissue	damage	by	non-organic	material,	and	to	malignantly	transformed	cancer	cells	
(2).	 Immune	cells	are	capable	of	producing	damage	 to	 living	cells,	 therefore	 inbuilt	 into	 the	
immune	system’s	design	is	its	ability	to	ignore	and	preserve	healthy	self-tissue	during	pathogen	
destruction	(1-3).	Since	pathogens	have	evolved	in	tandem	with	mammals,	the	immune	system	





and	 health	 (1,	 3).	 Thus,	 when	 functioning	 optimally,	 the	 immune	 system	 will	 eradicate	
dangerous	non-self	threats,	whilst	ignoring	benign	or	self-tissues.	Immune	cells	discriminate	





The	 ‘Innate’	 immune	 response	 comprises	 a	 range	 of	 cellular	 and	 non-cellular	 components.	
Whereas	 adaptive	 immune	 cell	 populations	 are	 pathogen	 specific,	 and	 clones	 of	 adaptive	
immune	 cells	 take	 time	 to	 expand	 in	 response	 to	 infection,	 innate	 effectors	 can	 respond	 to	
pathogens	more	generally	and	more	rapidly	(2,	4,	6).	Innate	immunity	therefore	functions	to	
limit	pathogen	replication	whilst	 the	more	efficient	killing	 function	of	 the	adaptive	 immune	
system	is	recruited.	Innate	cells	then	support	adaptive	immune	cell	functions	once	they	arrive	



































pathogens.	 PRRs	 developed	 during	 human-microbe	 co-evolution	 and	 respond	 to	 conserved	
structural	 features	 of	 microorganisms,	 known	 as	 Pathogen	 Associated	 Molecular	 Patterns	
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these	 enzymes	 results	 in	 the	 formation	 of	 C4b2a,	 and	C3	 is	 cleaved	 in	 a	 similar	manner	 to	
classical	complement	activation	(2,	5).		
	






at	mucosal	 surfaces,	where	 pathogens	 are	 likely	 to	 enter	 the	 body.	 Along	with	 other	 small	








The	 specific	 peptide	 sequence	 within	 the	 antigen	 which	 allows	 it	 to	 be	 recognised	 by	 the	




Lymphocytes	 depend	 upon	 somatic	 rearrangement	 of	 genes	 to	 generate	 receptors	 that	 are	










specific	 to	 that	 antigen	 to	 divide	 rapidly	 and	 form	 large	 clones	 (4).	 This	 process	 is	 slow,	
therefore,	 the	 innate	 immune	 system	 protects	 the	 body	 during	 the	 lag	 phase	 of	 adaptive	
immune	expansion	(2,	5).		
	
Days	 later,	 the	 adaptive	 immune	 response	 becomes	 predominant,	 but	 innate	 cells	 are	
continually	recruited	and	aid	lymphocytes	in	fully	eradicating	the	pathogen	(2,	5).	As	well	as	
antigen	 specificity,	 an	 important	 characteristic	 of	 adaptive	 immunity	 is	 that	 memory	 cell	
populations	are	produced	as	part	of	the	proliferative	phase.	Memory	cells	are	programmed	to	
divide	rapidly	should	the	specific	pathogen	be	encountered	subsequently,	meaning	that	the	lag	




B	 lymphocytes	 are	 a	key	 immune	 cell	 subset,	whose	principal	 function	 is	 the	production	of	
Immunoglobulin	(Ig).	Mature	B	cells	are	characterised	by	cell	surface	markers	including	CD79a,	
CD79b,	CD19,	 and	CD20	 (13).	Most	mature	B	 cells	 reside	within	 spleen,	 lymph	node	or	 gut	
































































cell	 until	 light	 chain	 rearrangement	 completes.	 The	 resultant	 receptor	 generated	 from	
rearranged	 heavy	 chains	 and	 surrogate	 light	 chains	 is	 called	 the	 pre-BCR	 (2,	 4,	 13).	 The	























the	 Germinal	 Centre	 (GC)	 reaction	 (13).	 The	 combination	 of	 signals	 received	 during	 this	
antigen-dependent	development	directs	mature	B	cells	down	one	of	 two	 lineages;	 the	short	
lived	effector	B	cell,	known	as	 the	plasma	cell,	or	 the	memory	B	cell	 (4).	There	are	 two	key	
events	which	occur	during	B	cell	activation	in	Germinal	centres,	Somatic	Hypermutation	(SHM)	
and	Class	Switch	Recombination	(CSR)(2,	4,	13).	B	lymphocytes	require	two	signals	for	T	cell	









When	B	 cells	 receive	 Signal	 1,	 transduction	occurs	 through	 the	B	 cell	 receptor	 (the	 surface	
bound	Ig)	as	well	as	its	associate	proteins	Iga	and	Igb	(2,	13).	Signalling	downstream	of	the	B	
cell	receptor	is	similar	to	T	cell	Receptor	signal	transduction,	which	will	be	discussed	in	detail	
























Hypermutation	 (SHM)	 introduces	 point	 mutations	 into	 the	 variable	 region	 to	 widen	 the	
diversity	of	the	antibody	repertoire	produced	(14,	15).	T	cell	dependent	activation	ensures	that	



















































Different	 pathways	 allow	 presentation	 of	 antigen	 found	 in	 extracellular,	 intracellular	 and	





























cells.	 CD8+	T	 cells	 then	kill	 the	 infected	 cell.	 Cross	presentation	occurs	only	 in	professional	











differences	 in	 the	 speed	 and	 characteristics	 of	 peptide	 presentation	 by	 MHC	 I	 (1,	 21).	
Polymorphisms	amongst	genes	encoding	MHC	I	are	also	linked	to	susceptibility	to	infection	and	




cells	 (1).	 Cellular	proteins	 are	degraded	by	 the	proteasome	at	 the	 end	of	 their	 life	 and	 this	
process	generates	peptides	for	Class	I	presentation	(10).	Certain	proteins	enter	the	proteasome	
directly	 after	 translation,	 these	 proteins	 are	 termed	 defective	 ribosomal	 products	 (DRiPs)	












free	MHC	 I	 heavy	 chains.	 If	 free	 peptide	 and	b2-M	 are	 available,	 the	MHC	 I	 complex	might	












the	phagosome	 for	degradation	 in	 the	cytoplasm.	Peptides	 then	either	enter	 the	ER	and	 the	
classical	 MHC	 I	 presentation	 pathway,	 or	 re-enter	 a	 unique	 phagosomal/endosomal	
compartment	 and	 are	 presented	 by	 MHC	 I	 found	 there	 (22,	 26).	 In	 the	 vacuolar	 pathway	













The	 peptides	 presented	 by	 MHC	 II	 originate	 outside	 the	 cell	 and	 are	 taken	 up	 into	 the	
endosomal	 compartment	 for	 degradation	 before	 being	 presented	 (1,	 10,	 21).	 MHC	 II	 is	 a	
heterodimeric	protein	made	up	of	a	and	b	chains	which	assemble	in	the	ER	and	form	a	complex	
with	 an	 invariant	 chain	 protein	 (Ii)	 before	 being	 transported	 into	 a	 specific	 part	 of	 the	
endosome	 known	 as	 the	 MHC	 Class	 II	 Compartment	 (21,	 29).	 Three	 MHC	 II	 heterodimers	
interact	 with	 one	 Ii	 trimer	 to	 form	 a	 complex	 which	 is	 stable	 in	 the	 endosome	 (29).	 The	
presence	of	Ii	is	thought	to	prevent	peptide	binding	within	the	ER	(30).	In	the	endosome,	part	




signalling	 from	 the	membrane	 inwards,	 or	 from	 the	 intracellular	 compartment.	 It	 has	 been	







through	T	 cell	 and	B	 cell	 receptors,	which	 cannot	 respond	optimally	 to	 peptide	 unless	 it	 is	
presented	in	the	context	of	MHC	(1,	10).	 In	addition,	 leukocytes	such	as	NK	cells	respond	to	
‘missing	self’	and	detect	foreign	cells	as	much	by	their	lack	of	self-MHC	as	by	their	expression	
of	 foreign	 antigen	 (32).	 For	 these	 reasons,	 it	 is	 not	 surprising	 that	 different	 alleles	 and	




T	 Lymphocytes	 are	 usually	 divided	 into	 four	 categories.	 Those	 expressing	 the	 ab	 T	 Cell	
Receptor	(TCR)	are	subdivided	into	CD4+	or	CD8+	T	cells,	with	different	key	functions	(4).	A	
third	T	cell	subset	express	a	gdTCR	and	a	fourth	T	cell	subset	are	CD4-CD8-	and	express	the	
































are	 therefore	 known	 as	 double	 negative	 (DN)	 thymocytes.	 The	 first	 double	 negative	
development	stage	is	termed	DN1,	and	it	 is	characterised	by	expression	of	CD44	and	lack	of	
















similar	manner	 to	 that	 described	 in	 VDJ	 recombination	within	 B	 cells,	 Tdt	 adds	 additional	






After	 b	 chain	 rearrangement,	 thymocytes	 downregulate	 CD44.	 This	 stage	 of	 thymocyte	




34).	 The	 pre-TCR	 complexes	 with	 CD3	 so	 that	 DN4	 thymocytes	 survive	 and	 proliferate,	





interaction	 with	 self-peptide-MHC	 (pMHC)	 complexes	 on	 thymic	 cortical	 epithelial	 cells	
(cTECs)	 (33).	 The	 interaction	 between	 thymocytes	 and	 self-	 antigens	 presented	 by	 cTECs	
allows	discrimination	between	thymocytes	with	functional	and	non-functional	ab	TCRs.	Those	
possessing	a	TCR	which	is	unable	to	respond	to	self-pMHC	with	sufficient	affinity	are	deemed	









the	 thymic	 medulla	 (33).	 Here,	 they	 again	 encounter	 self-antigen	 presented	 as	 pMHC	
complexes,	this	time	by	medullary	TECs	(mTECs)	and	professional	APCs	(33).		
	
Further	 negative	 selection	 occurs	 at	 the	 thymic	 medulla,	 making	 doubly	 certain	 that	
thymocytes	possessing	a	TCR	with	high	affinity	for	self-antigen	are	induced	to	die	by	apoptosis	
and	do	not	leave	the	thymus	(1,	33,	34).	Presentation	of	self-peptides	in	the	thymic	medulla	is	





tolerance	mechanisms,	 since	 it	 appears	 to	be	 the	 site	 of	 development	 for	T	 regulatory	 cells	









antigen	presentation,	 like	 lymphocytes	 (37).	 Furthermore,	 certain	microbes	 such	as	Human	
Cytomegalovirus	(HCMV)	can	induce	gd	T	cells	to	undergo	clonal	expansion	like	true	adaptive	













particularly	 advantageous	 in	 the	 host	 defence	 against	 tumours,	 since	 tumours	 may	















form	 a	 clone	 of	 antigen-specific	 effector	 cells.	 If	 a	 suboptimal	 combination	 of	 signals	 is	
encountered	 at	 priming,	 naïve	CD8+	T	 cells	may	become	 tolerant	 to	 the	 antigen	presented,	

































contacts	 the	 APC	 membrane.	 These	 clusters	 coalesce	 to	 form	 a	 larger	 island	 of	 signalling	
molecules	known	as	the	central	supramolecular	activation	cluster	(cSMAC).	We	have	shown	
that	the	ability	of	cells	to	form	a	cSMAC	is	directly	related	to	the	efficiency	of	TCR	signalling	as	
measured	 by	 the	 phosphorylation	 of	 intermediates	 downstream	 (47).	 Some	 TCR	 signalling	
proteins	 show	a	 predilection	 to	 accumulate	 in	 the	 region	 around	 the	 cSMAC,	 known	 as	 the	
peripheral	 SMAC	 (pSMAC).	 Thus,	 the	 complete	 immune	 synapse	 is	 often	 said	 to	 form	 a	





(cell	 couples)	between	T	cells	 and	Antigen	Presenting	Cells	 (APCs).	Genes	encoding	various	





top-down	view	shows	 the	view	 looking	at	a	T	cell-APC	couple	 from	above	(47).	The	central	
distribution	 and	 peripheral	 distribution	 represent	 the	 pSMAC	 and	 cSMAC,	 however	 some	
molecules	 occupy	 other	 domains	 in	 the	 immune	 synapse,	 indicating	 diverse	 patterning	 of	
different	signalling	receptors	during	T	cell	immune	synapse	formation	(47).		
	







































transcription	 factors;	 and	 the	 translocation	 of	 these	 transcription	 factors	 into	 the	 nucleus,	
where	 they	 promote	 CD8+	 T	 cell	 survival,	 production	 of	 IL-2	 and	 expression	 of	 the	 IL-2	
Receptor	(47,	49).	IL-2	is	the	cytokine	which	drives	CD8+	T	cell	proliferation	and	the	acquisition	
of	 effector	 function	 after	 priming.	 CD8+	 T	 cells	 receive	 IL-2	 signals	 in	 an	 autocrine	 and	
paracrine	manner	(50).	Other	main	effects	of	TCR	signalling	are	actin-reorganisation,	cell-cell	
adhesion,	and	translocation	of	the	Microtubule	Organising	Centre	to	the	immune	synapse	(51,	






















the	 idea	 that	 immune	 synapse	 formation	 forces	 the	 T	 cell	 and	 APC	membranes	 into	 close	







activity.	 ZAP70	 in	 turn,	 phosphorylates	 ITAMs	 on	 Linker	 for	 Activation	 of	 T	 cells	 (LAT),	 a	
scaffolding	protein	which	plays	a	key	role	in	the	recruitment	of	other	proteins	which	amplify	
the	TCR	 signal	 (49,	 57,	 59).	 The	protein	 complex	 formed	 around	LAT	 is	 known	 as	 the	 LAT	












by	 our	 lab	 to	 localise	 to	 the	 cSMAC	 (47).	 The	 correct	 aggregation	 of	 the	 TCR,	 the	 LAT	
signalosome	and	its	associates	appears	to	be	crucial	for	the	resultant	arms	of	TCR	signalling	to	




























polymerisation	 at	 the	 immune	 synapse	 as	 well	 as	 activating	 MEK	 signalling,	 leading	 to	















intracellular	 calcium	 elevation	 through	 its	 binding	 to	 calcium	 channels	 on	 the	 endoplasmic	














PIP3	which	 recruits	 Akt	 to	 the	 cell	membrane.	 Akt,	 as	well	 as	 exerting	 pro-survival	 effects,	























and	 proliferation.	 These	 cascades	 are	 the	 Calcium	 pathway,	 the	 Mitogen	 Activated	 Protein	
Kinase	(MAPK)	Pathway,	and	the	NF-kB	pathway	(49,	57).		
	










containing	Phosphatase	 1	 (SHP1),	 remove	 activating	phosphorylation	marks	 from	proximal	
proteins	 such	 as	 Lck	 and	 ZAP70	 (57).	 The	 addition	 of	 phosphorylation	marks	 can	 also	 be	
inhibitory.	Diacylglycerol	kinase	(DGK)	phosphorylates	DAG	to	inactivate	it	(57).		
Lck	is	controlled	by	both	phosphorylation	and	dephosphorylation.	Upon	TCR	engagement,	Lck	








The	 proportion	 of	 these	 different	 Lck	 states	 determines	 whether	 TCR	 signalling	 proceeds,	
because	active	Lck	is	required	for	signal	propagation	(53).	Therefore	the	balance	between	CD45	
activity	 (removal	 of	 phosphates	 at	 Y394	 and	 Y505),	 and	 that	 of	 Csk,	 (addition	 at	 Y505),	
determines	 the	 rate	 at	 which	 active	 Lck,	 and	 TCR	 signalling,	 is	 inhibited	 (53).	 After	 TCR	
stimulation,	 active	 Lck	 in	 the	 open	 conformation	 appears	 to	 preferentially	 localise	 to	 the	
immune	synapse	when	compared	 to	 inactive	Lck	(53).	Exclusion	of	CD45	during	 initial	TCR	
signalling	might	 also	 permit	 Lck	 activity	 to	 increase	 in	 the	 spatial	 confines	 of	 the	 immune	
synapse.	Control	of	the	activation	state	of	Lck,	and	its	subcellular	location	are	believed	to	be	
important	ways	in	which	immunoinhibitory	molecules	and	co-inhibitory	receptors	modulate	
TCR	 signal	 transduction	 (65,	 66).	 Other	mechanisms	 by	which	TCR	 signalling	 is	 controlled,	
besides	 phosphorylation,	 include	 internalisation	 of	 signalling	 molecules.	 As	 well	 as	 being	
required	for	signal	amplification	initially,	the	correct	formation	of	the	cSMAC	in	space	and	time	






Lck	 is	present	within	CD8+	T	 cells	 in	 three	main	phosphorylated	 forms,	 and	 the	balance	of	
availability	 of	 these	 phosphotypes	 affects	 the	 potential	 for	 successful	 TCR	 signalling	 (53).	
Autophosphorylation	of	Lck	p394	occurs	in	response	to	TCR	agonism	and	causes	Lck	to	assume	




phosphorylation	 marks,	 therefore	 dPho	 Lck	 can	 also	 remain	 active	 or	 become	 inactive	
depending	 on	 which	 site	 is	 dephosphorylated	 (53).	 Thus,	 both	 kinases	 and	 phosphatases	
control	the	function	of	Lck.	The	percentage	of	each	Lck	phosphotype	in	resting	Jurkat	T	cells	is	
indicated	according	to	recent	data	(53).	Human	naïve	T	cells	display	similar	percentages.	The	


























presented	at	 the	 target	cell	 surface	rather	 than	on	 the	surface	of	professional	APCs.	Correct	
immune	synapse	formation	between	the	TCR	of	the	CTL	and	peptide-MHC	I	on	the	target	cell,	
permits	exocytosis	of	cytotoxic	granules	containing	perforin	and	Granzyme-B	into	a	membrane	
defined	 region.	 This	 allows	 cytotoxic	 granules	 to	 act	 on	 the	 target	 cell	 and	 destroy	 it	 with	
minimal	collateral	damage	 to	surrounding	 tissue	 (1,	48,	67).	Perforin	channels	 insert	 in	 the	

















Furthermore,	 the	 threshold	 for	 CTL	 activation	 by	 TCR	 stimulation	 is	 lower	 at	 killing	when	









Nonetheless,	 TCR	 signalling	 still	 results	 in	 the	 formation	 of	 the	 cSMAC	 and	 pSMAC	 after	
interaction	with	target	cells	(48).		
	
A	crucial	event	occurring	downstream	of	CTL	TCR	engagement,	 is	 the	rearrangement	of	 the	
actin	cytoskeleton.	One	well-established	 function	of	actin-rearrangement	 is	 to	enable	MTOC	
translocation	 from	 its	 position	 behind	 the	 nucleus,	 to	 supply	 lytic	 granules	 at	 the	 immune	




























to	 pass	 through	 an	 actin	 meshwork,	 so	 a	 requirement	 for	 actin	 clearance	 amongst	 CTL	
necessitates	further	investigation	(71,	78).	
	
Rather	 than	 just	 forming	 a	 central	 patch	 or	 a	 ring,	 actin	 can	 occur	 in	many	patterns	 at	 the	
immune	synapse.	Figure	6	illustrates	actin	patterns	observed	using	live	cell	imaging	of	T	cell-
target-cell	 couples,	 in	 which	 the	 T	 cell	 expresses	 F-tractin	 (a	 GFP-conjugated	 form	 of	 F-
actin)(71).	Actin	patterning	at	the	immune	synapse	can	characterised	in	the	same	way	as	other	
signalling	 intermediates	 described	 in	 Figure	 3,	 with	 the	 most	 important	 distinction	 being	
between	‘Peripheral’	and	‘Asymmetric’	actin	patterns,	representing	a	full	or	partial	actin	ring	
respectively;	 and	 ‘Central’	 ‘Lamellal’	 or	 ‘Diffuse’	 patterns,	 which	 involve	 actin	 covering	 the	
cSMAC	 (47).	 The	 Actin	 maintenance	 and	 Clearance	 models	 disagree	 about	 which	 patterns	



















does	 not	 maintain	 sufficient	 stability.	 (B)	 The	 Actin	 Clearance	 model	 suggests	 that	 actin	
clearance	away	from	the	cSMAC	is	required	to	permit	granule	release	through	the	centre	of	the	

















CD4+	T	 cells	modulate	 the	 CD8+	 T	 cell,	 B	 cell	 and	 innate	 immune	 responses	 to	 pathogens,	
predominantly	by	releasing	different	cytokines.	To	date,	many	CD4+	T	cell	subsets	have	been	





CD4+	 T	 cells	 follow	 the	 same	 developmental	 path	 as	 CD8+	 T	 cells.	 However,	 an	 important	
distinction	 occurs	 at	 the	 terminal	 stages	 of	 CD4+	 Thymocyte	 development,	 allowing	 the	
formation	of	 regulatory	CD4+	T	 cells	 (79).	Mature	CD4+	Thymocytes	undergo	 two	possible	
fates.	Either,	CD4+	 thymocytes	become	naïve	CD4+CD25hiFOXP3+	natural	T	 regulatory	cells	
(nTregs),	 which	 are	 capable	 of	 downmodulating	 the	 immune	 response	 immediately	 after	






a	 contact-dependent	 fashion,	whereas	Tregs	which	develop	after	 thymic	 exit	 (peripheral	 or	
pTregs)	 tend	 to	modulate	other	 immune	 cells	 via	 cytokine	 release.	The	 role	of	 cytokines	 in	
nTreg-mediated	 suppression	 is	 not	 well	 understood,	 however,	 they	 are	 thought	 to	 require	














DCs	 then	prime	CD4+	T	cells,	 and	 the	DC-derived	cytokines	provide	Signal	3.	The	profile	of	




83).	 CD4+	 T	 cell	 subsets	 are	 therefore	 induced	 by	 distinct	 cytokines,	 express	 different	
transcription	factors	and	chemokine	receptors	and	produce	different	effector	cytokines	(Table	
1).	 The	 production	 of	 cytokines	 by	 DCs	 thus	 effectively	 acts	 as	 a	 messenger,	 relaying	
information	from	PAMPs	and	DAMPs	to	the	adaptive	immune	system,	to	ensure	that	CD4+	T	
cells	 activated	 at	 the	 lymph	 node	 are	 equipped	 to	 deal	 with	 the	 pathogen	 which	 was	
encountered	by	DCs	 in	 the	periphery	(79,	83).	However,	after	 lineage	acquisition	 in	CD4+	T	





Once	 activated,	 CD4+	 T	 cells,	 can	 stimulate	 DCs	 via	 CD40/CD40-Ligand	 interactions,	which	
make	DCs	more	efficient	at	 inducing	 further	T	cell	 responses	 (79).	A	subset	of	CD4+	T	cells	
migrate	to	lymph	node	germinal	centres	where	they	become	resident	T	follicular	helper	cells,	
whose	role	is	to	support	B	cells	during	somatic	hypermutation	and	class	switch	recombination,	




















pathogens,	 by	 producing	 cytokines	 such	 as	 IFNg.	 IFNg	 causes	 macrophages	 to	 upregulate	
phagocytic	activity	and	stimulates	CD8+	T	cells	to	kill	infected	or	damaged	self-cells	(79).	IFNg	
also	upregulates	MHC	I	expression	at	the	surface	of	infected	or	malignant	cells,	making	CD8+	T	
cell	 recognition	 more	 likely	 (83).	 Th2	 cells	 produce	 IL-4,	 IL-5	 and	 IL-13,	 which	 promote	
degranulation	of	eosinophils,	basophils	and	neutrophils	 in	response	to	 infection	with	 fungal	
Introduction	
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(82,	 87).	 In	 vitro	 primed	 pTregs	 are	 known	 as	 inducible	 Tregs	 (iTregs).	 TGFb	 induces	 the	
formation	 of	 pTreg	 in	 the	 periphery	 and	 in	 vitro,	 provided	 IL-2	 is	 present.	 Without	 IL-2,	
expansion	of	CD4+CD25-	T	cell	activation	 in	 the	presence	of	TGFb	produces	 tolerant	T	cells	
which	are	unresponsive	to	re-stimulation	(87).	The	addition	of	TGFb	to	cultures	of	CD8+	T	cells	
also	produces	CD8+CD103+	Treg	cells	with	regulatory	abilities	such	as	IL-10	production	(88).	
CD4+FOXP3+	 pTreg	 have	 been	 shown	 to	 develop	 into	 inflammatory	 Th17	 cells	 under	







presence	 of	 the	 cytokine	 IL-10.	 Tr1	 cells	 suppress	 in	 several	 characteristic	 ways,	 mostly	


















amongst	 T	 cells	 occurs	 during	 clonal	 expansion	 and	 they	 eradicate	 pathogen	 (94).	 Besides	
acquiring	 effector	 function,	 it	 is	 now	 known	 that	 T	 cells	 can	 develop	 other	 fates	 between	
priming	and	death.	For	clarity,	 these	fates	are	defined	separately	as	Memory,	Tolerance	and	








Naïve	T	 cells	 can	acquire	 several	 fates	depending	on	 the	 conditions	 they	experience	during	





entering	 the	 peripheral	 repertoire	 (34).	 Foreign	 antigen	 is	 usually	 encountered	 by	 DCs	 in	
association	 with	 pathogenic	 and	 damage	 molecules	 which	 activate	 DCs,	 causing	 them	 to	







95).	 After	 successful	 eradication	 of	 acute	 infection,	 Teff	 cells	 transiently	 produce	 IL-10	 and	
upregulate	co-inhibitory	receptors	to	induce	contraction	of	the	immune	response.	Many	Teff	
become	senescent	but	a	few	cells	possess	the	ability	to	form	self-renewing	memory	populations	
(Tmem)	 which	 exhibit	 accelerated	 expansion	 and	 pathogen	 clearance	 if	 the	 infection	 is	
encountered	again	(12,	45,	95).		
	
If	 the	 immune	 response	 cannot	 successfully	 eradicate	 pathogen,	 such	 as	 in	 chronic	 viral	
infections	and	cancer,	the	continued	presence	of	antigen	induces	exhaustion	amongst	T	cells	
(right	 downward	 arrow).	 Prolonged	 and	 high-level	 expression	 of	 IL-10	 and	 co-inhibitory	
receptors	causes	Teff	cells	to	acquire	an	exhausted	phenotype	(Tex).	The	release	of	cytokines	
including	 TGFb,	 IL-10	 and	 IL-27	 by	 exhausted	 and	 regulatory	 immune	 cells	 supports	 the	
transition	 to	 Tex	 cells	 (93,	 95).	 The	 acquisition	 of	 exhaustion	 is	 associated	 with	 the	
upregulation	of	transcription	factors	such	as	EOMES	and	T-bet,	which	regulate	different	genes	







of	 abortive	 activation	 or	 tolerance	 (Ttol)(42,	 97).	 The	 development	 of	 tolerance	 is	 further	
encouraged	through	signal	3,	in	the	form	of	anti-inflammatory	cytokines	such	as	IL-10,	TGFb	
and	 IL-27,	 released	 by	 T	 regulatory	 (Treg)	 cells.	 Ttol	 cells	 exhibit	 diminished	 responses	 to	



















Optimal	 priming	 causes	 many	 T	 cells	 to	 form	 rapidly	 expanding	 clones	 of	 effectors	 which	
contract	and	die.	However,	some	T	cells	become	longer	 lived	memory	cells	which	retain	the	
ability	 to	rapidly	proliferate	and	exert	effector	 functions.	 If	antigen	 is	encountered	a	second	


















are	 not	 actively	 dividing	 and	produce	 little	 to	 no	 IL-2.	 They	 are	 identified	 by	 the	 signature	
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CD62Llow,	 CD44+,	 CD69-,	 CD103a-.	 Conversely,	 CD8+	 T	 Central	 Memory	 cells	 are	 hugely	
effective	 at	 antigen-responsive	 proliferation	 and	 migration	 but	 less	 effective	 killers;	 they	
express	CD62Llow,	CD44+,	CD69-,	CD103a-	(102).	Memory	T	cell	populations	are	maintained	in	













During	 chronic	 viral	 infection,	 the	 pathogen	 evades	 eradication	 and	 antigen	 is	 chronically	
present.	In	this	scenario,	the	host	protects	itself	from	persistent	immune	activity	by	diverting	T	
cells	towards	a	fate	known	as	Exhaustion,	in	which	they	lose	effector	function	(93).	Exhaustion	
is	 therefore	 a	 host-determined,	 protective	 response	 to	 chronic	 antigen	 in	 which	 the	 body	
sacrifices	 pathogen	 clearance,	 to	 prevent	 immune	 damage	 to	 tissues	 through	 persistent	



















The	 loss	of	effector	 functions	by	exhausted	T	cells	occur	 in	a	stepwise	 fashion	 in	peripheral	
tissues	 (111).	 Firstly,	 proliferative	 ability	 is	 lost,	 along	 with	 effector	 cytokine	 production.	
Amongst	CD8+	T	cells	taken	from	acute	infection,	the	progressive	loss	of	IL-2,	IFNg	and	TNF-a	




After	 altered	 cytokine	production,	 exhausted	T	 cells	 exhibit	 alterations	 in	migratory	 ability.	
Studies	in	Lymphocytic	Choriomeningitis	Virus	(LCMV)	infection	have	shown	that	CD8+	T	cells	
in	 the	 secondary	 lymphoid	 tissues	 lose	expression	of	CD44	and	CD62L	during	 chronic	viral	
infection,	when	compared	to	acute	stimulation.	This	results	in	an	impaired	ability	of	CD8+	T	







of	 co-inhibitory	 receptors	 (CIRs)	 on	 their	 surface,	 including	 CTLA-4,	 PD-1,	 Lymphocyte	













of	 antigenic	 stimulation	 correlates	 with	 more	 severe	 and	 irreversibly	 exhausted	 T	 cell	
phenotypes,	and	with	deletion	of	exhausted	T	cells	(95,	111,	113,	114).	Early	intervention	in	
HCV	 and	 HBV	 treatment,	 which	 removes	 the	 chronic	 viral	 stimulus,	 appears	 to	 alter	 the	
progression	of	CD8+	T	cells,	preventing	them	from	becoming	exhausted	(95,	113).	Continuous	













Blockade	 of	 more	 than	 one	 inhibitory	 receptor	 is	 required	 to	 efficiently	 reverse	 T	 cell	
exhaustion	in	a	variety	of	viral	and	tumour	settings	(103,	115,	117).	Evidence	from	models	of	
CMV	suggest	that	in	various	diseases	different	CIRs	could	act	as	major	and	minor	regulators	of	













been	 identified	which	 is	 associated	with	 co-expression	 of	 TIM3,	 LAG3,	 TIGIT,	 PD-1	 and	 the	
cytokine	 IL-10	 (121)	 (Figure	 8).	 The	 transcription	 factors	 Prdm-1	 and	 c-Maf	were	 induced	
downstream	of	IL-27	signalling	and	promoted	expression	of	this	CIR	module	(121).	Prdm-1	and	
c-Maf	 knockout	 CD8+	 TILs	 did	 not	 develop	 an	 exhausted	 genotype	 within	 the	 tumour	












of	 three	 mechanisms:	 spatial	 segregation	 of	 TCR	 signalling	 components	 to	 impair	 cSMAC	
formation;	 altered	 location	 or	 activation	 of	 TCR	 and	 cytokine	 signalling	 intermediates;	 or	
altered	transcription	of	inflammatory	genes	and	induction	of	anti-inflammatory	gene	targets	














Cell	 Death	 Protein-1	 (PD-1),	 Lymphocyte	 Activation	 Gene	 3	 Protein	 (LAG3),	 T-cell	
Immunoglobulin	 and	 Mucin-domain	 containing-3	 (TIM3),	 T	 cell	 Immunoreceptor	 with	






































phosphatases	 downstream	 of	 CTLA-4	 ligation	 (123).	 Furthermore,	 CTLA-4	 signals	 back	 to	
APCs,	 causing	 them	 to	 release	 indoleamine-2,3-dioxygenase	 (IDO),	 which	 inhibits	 T	 cell	
function	(123).	Therefore,	CTLA-4	expression	on	effector	T	cells	limits	activation	of	the	T	cell	










SHP-1	 and	 SHP-2	 to	 its	 Immunoreceptor	 Tyrosine	 based	 Switch	 Motif	 (ITSM),	 thereby	
inhibiting	 TCR	 signalling	 through	 de-phosphorylation	 of	 key	 TCR	 signalling	 intermediates	




Ras,	PI3K	and	AKT	signalling	(95).	Some	studies	suggest	 that	PD-1	also	exerts	 its	 inhibitory	
effect	by	antagonising	the	effects	of	CD28	co-stimulation	and	thus,	re-invigoration	of	the	T	cell	
immune	response	in	the	presence	of	PD-1	blockade	could	rely	on	CD28	signalling	(119).	For	
this	 reason,	 blockade	of	CTLA-4	and	PD-1	has	been	 shown	 to	produce	 synergy	 in	 restoring	
exhausted	T	cells	to	effector	function	(119).		
	




vitro	 models	 of	 exhaustion	 fail	 to	 produce	 many	 of	 the	 phenotypes	 seen	 in	 vivo,	 notably	
defective	T	cell	migration,	infiltration	and	altered	transcription	of	effector	genes	such	as	BATF	
(95).	Use	of	IL-27	to	promote	expression	of	multiple	CIRs	at	once	could	allow	us	to	generate	
better	models	of	 exhaustion,	 including	PD-1	 signalling,	 in	 vitro.	 In	addition,	 the	 longevity	of	
antigen	signalling	experienced	during	chronic	viral	infection	and	cancer	is	much	greater	when	
compared	to	short	term	in	vitro	cultures	(76).	Other	work	has	also	identified	different	roles	of	











Therefore,	 the	 balance	 of	 expression	 of	 CD226	 versus	 TIGIT	 determines	 whether	 CD155	
produces	stimulatory	or	inhibitory	effects	on	T	cells	(120,	125).	CD96	is	another	receptor	for	










recently	 been	 shown	 to	 directly	mediate	 downregulation	 of	 TCR,	 CD3	 and	 PLCg	molecules,	
















LAG3-FLG-1	 interactions	 could	 require	 blockade	 in	 order	 to	 improve	 anti-tumour	 immune	
responses	 (126).	 The	 intracellular	 pathways	 which	 occur	 downstream	 of	 LAG3-FLG-1	
interactions	 remain	 to	be	determined	 (121).	Galectin-3	and	LSECtin	 (Liver	and	 lymph	node	











cells	 in	 the	 immune	 system	 is	 undisputed.	 The	 discovery	 of	 TIM3	was	 achieved	 during	 the	
search	for	regulators	of	Th1	immunity	using	a	model	of	experimental	autoimmune	encephalitis	
(EAE),	 in	 which	 the	 authors	 noted	 that	 anti-TIM3mAb	 treatment	 accelerates	 disease	
progression	 and	 increases	 the	 number	 of	 inflammatory	 lesions	 (128).	 At	 this	 time,	 the	









gene	 are	 associated	 with	 Subcutaneous	 panniculitis-like	 T	 cell	 lymphoma,	 a	 rare	 cancer	
associated	 with	 auto-immune	 syndromes	 which	 is	 treatable	 through	 immunosuppression	
(130).	Conversely,	TIM3	is	expressed	at	aberrantly	high	levels	amongst	immune	cells	in	chronic	
viral	 infections	 and	 cancers,	where	 immune	exhaustion	 contributes	 to	pathology	 (116,	120,	
129,	131,	132).	TIM3+	cells	are	elevated	in	the	blood	of	patients	with	chronic	viral	infections;	
including	HIV,	Hepatitis	B	and	Hepatitis	C	viruses	(HBV,	HCV)(120).	TIM3+	NK	cells	assist	in	
the	maintenance	of	maternal	 tolerance	 to	 fetal	antigens	 (133).	TIM3+PD-1+	cells	have	been	
identified	as	one	of	the	most	suppressed	populations	of	CD8+	T	cells	within	tumours,	due	to	
their	 inability	 to	 produce	 IL-2,	 IFNg	 and	 TNF-a,	 hence	 TIM3	 plays	 a	 key	 role	 in	 immune	
suppression	 by	 the	 tumour-microenvironment	 (116,	 129,	 131).	 However,	 the	 group	which	
postulated	that	TIM3+PD-1+	cells	are	the	most	suppressed	populations	within	tumours	did	not	



















NFIL3.	 Thus,	 several	 transcription	 factors	 have	 been	 identified	 as	 regulators	 of	 TIM3	
expression,	 including	ETS-1/NFIL3	and	Prdm-1/c-Maf.	However,	 IL-27	signalling	appears	 to	
feed	into	both	pathways,	making	IL-27	crucial	for	TIM3	expression	(116,	120,	121,	135,	137).	



































containing	 proteins	 in	 the	 place	 of	 Bat3	 could	 be	 responsible	 for	 this	 effect	 (120).	 Thus	
sequestration	of	Lck	away	from	the	immune	synapse,	and	replacement	of	Bat3	by	inhibitory	











55,	 138).	Hence,	 unless	 an	 inhibitory	 ligand	 is	 present,	 TIM3	 lowers	 the	 threshold	 for	 TCR	
signalling.	 (B)	 Illustrates	 the	 proposed	 localisation	 of	 Lck	 when	 TIM3	 is	 engaged	 by	 an	
inhibitory	ligand.	After	TIM3	engagement	by	Ceacam-1	or	Galectin-9,	BAT	3	detaches	from	the	
TIM3	cytoplasmic	tail,	and	with	it	removes	a	pool	of	Lck,	reducing	the	potential	for	TCR	signal	






























cells.	 PSer	 appears	 to	be	particularly	 important	 for	TIM3	 signalling	 in	 innate	 immune	 cells,	
however	it	is	unknown	whether	PSer	binding	to	TIM3	expressed	on	lymphocytes,	feeds	back	
into	 lymphocyte	 function	 (127).	 It	 has	 been	 proposed	 that	 there	 is	 a	 link	 between	 PSer	
engagement	of	TIM3	and	IL-10	production	by	lymphocytes,	however	the	mechanism	behind	
this	 association	 remains	 to	 be	 demonstrated	 (134,	 135,	 137).	 PSer	 engagement	 of	 TIM3	
expressed	 on	 macrophages	 encourages	 phagocytosis	 of	 apoptotic	 bodies,	 however,	
engagement	of	TIM3	on	lymphocytes	does	not	lead	them	to	acquire	phagocytic	abilities	(127).	
If	 apoptotic	 bodies	 are	 not	 removed	 by	 the	 immune	 system	 their	 presence	 leads	 to	 the	
development	 of	 auto-reactive	 antibodies	 and	 autoimmune	 syndromes,	 thus	 PSer-TIM3	




High	 Mobility	 Group	 Protein	 B1	 (HMGB1)	 is	 another	 ligand	 which	 strongly	 affects	 innate	
immunity	when	binding	 to	TIM3	 (120).	Whereas	binding	of	PSer	 to	TIM3	expressed	on	DC	
appears	to	assist	DC	in	their	uptake	of	apoptotic	bodies,	binding	of	HMGB1	to	TIM3	limits	the	
other	 uptake	 ability	 of	 DCs,	 their	 ability	 to	 process	 DNA	 or	 RNA	 (120).	 HMGB1	 normally	




key	 step	 required	 for	DC	 activation	 and	maturation	within	 tumours,	 therefore	 limitation	 of	
nucleic	acid	uptake	by	TIM3	signalling	prevents	DC	maturation	and	effective	presentation	of	
tumour	antigens	to	prime	anti-tumour	T	cells	(120,	134).	Ceacam-1	and	HMGB-1	demonstrate	



























alongside	 expression	 of	multiple	 combinations	 of	 CIRs	 is	 associated	with	 T	 cell	 exhaustion	
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during	chronic	 infections	such	as	LCMV,	or	 in	tumours,	where	IL-10	is	encountered	for	 long	
periods	alongside	other	tolerogenic	stimuli	(95).		
	
IL-10	 is	 also	 known	 to	 inhibit	 the	 production	 of	 TNF-a	 and	 IL-1b	 by	 macrophages	 and	













































and	 phenotypic	 T	 cell	 fate	when	 compared	 to	 either	 regulatory	 T	 cells	 or	memory	 T	 cells.	
Transcriptional	regulation	of	genes	which	regulate	metabolism	and	inflammatory	responses	is	
markedly	 altered	 during	 exhaustion	 (95).	 Key	 transcription	 factors	which	 are	 expressed	 in	
exhausted	T	cells	include	T-bet	and	EOMES.	Factors	such	as	the	availability	of	pro-inflammatory	
cytokines	 from	 CD4+	 T	 helper	 cells,	 and	 the	 strength	 and	 duration	 of	 chronic	 antigen	
engagement,	 produce	 heterogenous	 populations	 of	 exhausted	 cells	 with	 different	 gene	
expression	profiles	(95).	Whereas	FOXP3	is	a	canonical	transcription	factor	of	nTreg	and	pTreg	
cells,	 a	 genetic	 biomarker	 of	 exhausted	 cells	 has	 not	 yet	 been	 identified	 (82,	 95).	 The	
identification	of	a	specific	biomarker	of	exhausted	cells	would	be	useful,	to	allow	the	accurate	







































self-antigen	 could	 still	 proceed	 successfully.	 This	 rarely	 occurs,	 because	 DCs	 executing	
immunosurveillance	 for	pathogens	generally	do	not	encounter	self-antigen	 in	 the	context	of	
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However,	 although	 tolerant	 T	 cells	 are	 less	 responsive	 than	 exhausted	 T	 cells	 to	 TCR	
stimulation,	in	some	cases	T	cells	may	recover	from	either	tolerance	or	exhaustion	(42).	Ex	vivo	
expansion	with	IL-15	or	in	vivo	expansion	in	response	to	lymphodepletion	are	two	methods	by	















Immune	 ignorance	 is	 another	 tolerance	mechanism	whereby	 physical	 barriers	 such	 as	 the	
blood	brain	barrier	create	 immunoprivileged	sites	 in	the	body	which	cannot	be	accessed	by	










IL-27	 make	 up	 Signal	 3	 (88,	 95,	 150).	 Similarly,	 exposure	 to	 chronic	 antigen	 can	 produce	
regulatory,	rather	than	exhausted	T	cells,	under	certain	conditions.	There	is	some	functional	
overlap	between	exhausted	and	regulatory	T	cells,	since	exhausted	T	cells	produce	IL-10	and	






nTreg)	or	 adaptively	 generated	 in	 the	periphery	 (CD8+	pTreg).	 In	CD8+	T	 cells,	 there	 is	no	
marker	which	differentiates	naturally	occurring	and	peripheral	CD8+	Tregs.	CD4+	and	CD8+	
nTregs	express	FOXP3	and	CTLA-4	and	suppress	in	a	similar,	contact	dependent	manner	(151).	
It	was	 thought	 that	 professional	 CD8+	pTregs	 did	 not	 exist,	 and	 that	 CD8+	T	 cells	 exerting	
regulatory	functions	were	simply	exhausted	cells	producing	transient	IL-10.	However	distinct	










engage	 ligands	on	DCs	to	 limit	 their	antigen-presenting	abilities	(152).	Contact-independent	
mechanisms	of	Treg	suppression	include	excessive	binding	to	IL-2,	sequestering	it	away	from	
effectors,	and	production	of	 the	 immunosuppressive	cytokines	IL-10,	TGFb	and	IL-35	(153).	







calcium	 stores	 within	 T	 effector	 cells,	 however	 the	 mechanism	 for	 this	 finding	 remains	
unknown	(152).	Therefore,	Tregs	inhibit	the	efficacy	of	T	cells	at	priming	and	proliferation	in	









alterations,	 resulting	 in	 the	 acquisition	of	 traits	which	 induce	harm	 to	normal	 tissues	 (155,	













Sustained	 proliferative	 signalling	 is	 achieved	primarily	 through	Growth	 Factors	 (GF)	which	
signal	 through	 receptor	 tyrosine	 kinases.	 In	 normal	 cell	 populations	 the	 magnitude	 of	 GF	
signalling,	and	therefore	cell	growth	and	entry	into	cell	division	is	tightly	regulated,	however	
cancers	 either	 elevate	 GF	 signalling,	 or	 become	 able	 to	 signal	 independently	 of	 GFs.	 For	







they	 can	 continue	 to	 grow	 in	 the	 crowded	 and	 hypoxic	 conditions	 of	 the	 TME	 (157).	 For	








are	 acquired	 in	 order	 for	 normal	 cells	 to	 become	 transformed	 cancer	 cells	 (156).	 These	
hallmarks	 represent	 adaptations	 which	 allow	 cancer	 cells	 to	 possess	 a	 survival	 advantage	
within	 the	 tumour	 microenvironment	 (TME).	 The	 6	 original	 hallmarks	 are	 sustained	
proliferative	signalling;	evasion	of	growth	suppression;	acquisition	of	invasive	and	metastatic	
abilities;	resistance	to	apoptosis;	replicative	immortality,	and	the	induction	of	angiogenesis	in	

























on	 the	 activation	 of	 two	 pro-apoptotic	 proteins,	 Bax	 and	 Bak,	 which	 result	 in	 release	 of	
cytochrome-c	 from	 the	 mitochondria,	 initiating	 a	 cascade	 of	 caspase	 protein	 activation	
culminating	in	cell	death	(155,	161).	An	example	of	a	key	survival	signal	which	is	upregulated	
in	many	cancers	including	prostate,	colon	and	lung	carcinomas,	glioblastoma,	melanoma	and	




programmed	 to	 exit	 cell	 division	 after	 a	 set	 number	 of	 divisions.	 The	 finite	 number	 of	 cell	
divisions	is	indicated	by	progressive	telomere	shortening	with	each	division.	However,	cancer	
cells,	 which	 are	 known	 as	 immortalised	 because	 of	 their	 capacity	 for	 limitless	 replication,	


















represents	 a	 powerful	 mechanism	 by	 which	 tumours	 can	 be	 combatted,	 angiogenesis	 is	 a	
perfect	example	of	a	pro-tumorigenic	process	which	is	initiated	by	immune	cells	(155,	163).		
	
As	 well	 as	 acquiring	 new	 vasculature,	 a	 key	 hallmark	 of	 cancer	 cells	 is	 the	 acquisition	 of	
metastatic	 potential	 (155).	 Cancer	 cells	must	 invade	 surrounding	 blood	 and	 lymph	 vessels,	
traffic	through	them,	and	escape	at	distant	body	sites	to	form	new	tumours.	Key	regulators	of	
this	process	include	transcription	factors	involved	in	Epithelial-Mesenchymal	transition	(EMT),	













cancer	 development,	 and	 the	 TME	 has	 its	 own	 hallmarks.	 An	 important	 implication	 of	 the	
concept	of	the	TME	is	that	the	study	of	the	molecular	characteristics	of	cancer	cells	themselves	

















switch	 from	 oxidative	 phosphorylation	 to	 glycolysis	 as	 their	 chief	 use	 of	 glucose.	 This	




The	 hallmarks	 of	 cancer,	 however,	 are	 not	 accrued	 by	 all	 cells	within	 the	 tumour.	 Usually,	
cancers	arise	from	a	heterogenous	population	of	cells,	of	which	only	a	few,	termed	cancer	stem	
cells	 (CSCs)	 are	 able	 to	 actively	 generate	new	 tumours	by	developing	hallmarks	 (167).	 Cell	
surface	markers	have	been	developed	which	 identify	CSC	populations	 in	a	variety	of	human	
tumours,	 and	 they	 activate	 characteristic	 signalling	 pathways	 which	 give	 CSCs	 stem-like	
abilities.	Activation	of	the	Wnt/b-catenin,	Notch	and	PI3k	pathways	is	characteristic	of	CSCs	
(167).	These	pathways	represent	three	of	the	ten	pathways	cited	by	The	Cancer	Genome	Atlas	












if	 new	 selection	 pressures	 are	 encountered	 (167).	 Furthermore,	 cells	 without	 intrinsic	
stemness	can	be	induced	to	acquire	CSC	properties	due	to	signalling	within	the	TME	(167).	For	
this	 reason,	 cancers	 rapidly	 acquire	 resistance	 to	 drugs	 targeted	 at	 them,	 because	 cell	
populations	which	lack	the	drug	receptor,	or	possess	a	redundant	pathway	to	the	one	being	









infiltrate	 with	 respect	 to	 tumour	 growth	 (169).	 Chronic	 pro-inflammatory	 signalling	 can	
propagate	tumour	initiation	in	non-cancerous	tissue,	invoking	wound	healing	responses	which	
upregulate	 pathways	 involved	 in	 transformation,	 angiogenesis	 and	 metastasis	 (155,	 169).	
However,	 in	 established	 cancers,	 immune	 cells	 can	 directly	 lyse	 cancer	 cells	 and	 mediate	




The	 interaction	 between	 the	 immune	 system	 and	 tumours	 is	 now	 described	 as	 cancer	
immunoediting,	 because	 the	 immune	 response	 to	 an	 individual	 tumour	 can	 shape	 the	
phenotype	of	 that	particular	 cancer	 (139,	169).	 Immunoediting	occurs	over	 three	phases	of	
tumour	interaction	with	the	immune	system,	termed	Elimination,	Equilibrium	and	Escape	(169,	






















T	 cells.	 T	 cell	 dysfunction	 within	 tumours	 can	 be	 related	 to	 exhaustion,	 because	 cancers	
represent	a	source	of	chronic	antigen,	and	to	tolerance,	because	many	cancer	antigens	are	self-












and	 other	 tissues.	 Many	 TAA	 display	 tissue-specific	 expression,	 for	 example	 Melan-A	 is	




response	even	though	it	 is	a	TAA	and	not	a	TSA	(176).	 It	 is	now	thought	that	most	tumours	
express	TSA	or	at	 least	highly	TAA	at	some	stage	 in	 their	development.	Therefore	 there	are	
antigens	which	can	effectively	be	 targeted	by	 the	 immune	system	 in	most	cancers	 (176).	 In	
addition,	the	expression	of	TSA	is	favoured	in	tumours	with	a	high	mutational	burden	such	as	
melanoma	 or	 lung	 cancer,	where	 genomic	 instability	 is	 caused	 by	 ultraviolet	 radiation	 and	
smoking	respectively.	Many	mutations	that	enable	tumours	to	be	recognised	by	the	immune	
system	are	random,	generated	by	DNA	damage	or	defects	in	DNA	repair,	and	they	usually	differ	







to	 prime	 anti-tumour	 T	 cells	 even	 if	 the	 tumour	 expresses	 self-antigen,	 as	 long	 as	 damage	
signalling	is	present	to	induce	DC	maturation.	However,	if	damage	signalling	within	the	tumour	





drift	 is	 often	 seen	 within	 immunogenic	 tumours	 (174).	 Cancers	 also	 downregulate	 the	









































factors	which	are	encountered	once	T	cells	 reach	 the	TME	can	also	prevent	 infiltration.	For	
example,	 reactive	 oxygen	 species	within	 the	TME	 can	nitrosylate	 chemokines	 such	 as	CCL2	
which	are	important	for	the	recruitment	of	CD8+	T	cells	(178,	180).	As	well	as	disruption	of	
chemokine	signalling,	tumours	possess	abnormal	blood	vessel	morphology	(178).	The	presence	









factors	which	are	unique,	 or	disproportionately	upregulated	 in	 tumours	when	 compared	 to	
other	scenarios.	These	 include:	cell	 types	such	as	myeloid	derived	suppressor	cells	 (MDSC),	













IL-6,	 VEGF,	 PGE2,	 and	Granulocyte	Macrophage	 -Colony	 Stimulating	 Factor	 (GM-CSF)	 (185).	
TIM3	 engagement	 of	 Galectin-9	 on	 cells	 of	 the	 monocytic	 lineage	 also	 induces	 MDSC	
development	(134).	MDSC	are	divided	into	a	CD11b+LY6G+LY6Clowgranulocytic	subset,	and	a	
CD11b+LY6G−LY6Chi	 monocytic	 subset	 (185).	 MDSC	 can	 perform	 certain	 functions	 of	 both	
granulocytes	and	monocytes,	but	they	also	suppress	T	cells	by	several	mechanisms.	The	activity	






















CIRs	 are	 receptors	 expressed	 on	 the	 surface	 of	 immune	 cells	 which,	 when	 engaged,	
downregulate	 inflammatory	 activity.	 Physiologically,	 they	 help	 to	 downregulate	 normal	


















differentially	 regulated	 in	 the	 tumour	 and	 in	 peripheral	 sites,	which	may	 allow	TIM3	 to	 be	
targeted	therapeutically	in	cancer	without	producing	systemic	autoimmunity	(116,	188).		




upregulated	 amongst	 NK	 cells	 in	 cancer	 and	 TIM3	 expression	marks	 dysfunctional	 NK	 cell	
populations	 (120).	 TIM3+FOXP3+	 Tregs	 from	 tumours	 produce	more	 IL-10	 and	 TGF-b	 and	
express	 greater	 levels	 of	 CD39	 than	 those	without	 TIM3.	 In	 CD8+	TILs,	 TIM3	 expression	 is	
associated	with	a	loss	of	IFNg	production	and	TIM3	expression	by	tumour	cells	themselves	is	






TIM3	 expression	 can	 also	 be	 used	 as	 a	 prognostic	 biomarker	 in	 cancer	 patients	 (116).	 The	












important	 in	 mediating	 T	 cell	 exhaustion	 during	 chronic	 infection,	 there	 are	 some	 soluble	
mediators	of	 immunosuppression	which	are	predominantly	 seen	within	 cancers.	Adenosine	
and	 Prostaglandin-	 E2	 (PGE2)	 are	 two	 mediators	 which,	 although	 they	 are	 transiently	









anti-inflammatory	 medicines.	 However,	 chronic	 exposure	 to	 PGE2	 limits	 effector	 function	








PGE2	 is	 particularly	 important	 in	 colorectal	 carcinomas.	 One	 mechanism	 by	 which	 PGE2	
accumulates	in	these	cancers,	is	a	tumour-associated	mutation	in	the	gene	encoding	15-PDGH,	













via	 purinergic	 PX2R	 receptors,	 whereas	 adenosine	 is	 predominantly	 immunosuppressive,	
therefore	the	conversion	of	ATP	to	adenosine	represents	a	switch	by	which	 inflammation	 is	
downregulated	(194).	The	production	of	adenosine	is	a	protective	response	triggered	by	the	














receptors	 are	 predominantly	 pro-inflammatory,	 A2a	 and	 A2b	 receptors	 produce	
immunosuppressive	effects	(140,	182-184,	191,	200).	Of	these,	A2a	receptors	(A2aRs)	are	the	







Although	 the	 exact	mechanism	by	which	A2a	Receptor	 engagement	 inhibits	CD8+	T	 cells	 is	






z	 chain	phosphorylation	 and	 to	be	 associated	with	 reduced	 IL-2	production	 (65,	 203,	 204).	
Furthermore,	the	pre-clinical	benefit	of	A2aR	antagonism	in	models	of	murine	cancer	is	lost	if	
IFNg	 is	 neutralised,	 suggesting	 that	 A2aRs	 directly	 affect	 cytokine	 production	 by	 CD4+	 and	
CD8+	T	cells.	TNFa	and	IFNg	production	by	A2aR-/-	Chimeric	Antigen	Receptor	(CAR)	CD8+	T	











Csk	 and	 brings	 Csk	 into	 spatial	 contact	 with	 lipid	 rafts	 containing	 Lck,	 allowing	 it	 to	 add	
phosphorylation	to	Lck505	and	produce	the	inactive	Lck	form	(65,	203,	204).	Protein	Kinase	A	
type	I	 (PKA)	which	 is	constitutively	associated	with	TCR	microclusters,	 localises	at	elevated	
levels	in	response	to	increased	cAMP	accumulation,	and	further	activates	Csk	in	its	location	at	
the	 immune	 synapse	 (65,	 202).	 Thus,	 a	 cAMP-PKA-Csk	 axis	 acting	 to	 reduce	 Lck	 activity	
represents	 one	mechanism	 by	which	 adenosine	 signalling	 could	 negatively	 regulate	 T	 cells	
(Figure	12).	Blocking	PKA	produces	an	improvement	in	T	cell	production	of	IL-2	in	cells	taken	





downstream	 mediators	 of	 TCR	 signalling,	 inhibiting	 NFAT	 nuclear	 translocation,	 Ras-Raf	




As	 well	 as	 directly	 influencing	 TCR	 signalling,	 PKA	 regulates	 actin	 dynamics	 and	 cell	
morphology	 in	several	 cell	 types.	 In	 lymphocytes,	 cAMP	could	 influence	cell	morphology	by	
elevating	 PKA-mediated	 phosphorylation	 of	 the	 Rho	 GTPase,	 RhoA	 (206,	 207).	 PKA	 can	 be	













interaction	 between	 RhoA	 and	 ROCK.	 This	 would	 lead	 to	 reduced	 myosin	 light	 chain	






impairs	microcluster	 formation	 and	 actin-polymerisation	 at	 the	 immune	 synapse,	 thus	PKA	










upregulation	of	 the	gene	module	controlling	CIR	expression	and	 IL-10	production	 in	T	cells	
(121,	 144).	 A	 cAMP/PKA	 axis	 has	 been	 shown	 to	 increase	 IL-27	 production	 by	 increasing	
binding	 of	 cyclic	 AMP	 response	 element	 binding	 protein	 (CREB)	 to	 the	 IL-27	 promotor.	
Although	CREB	is	produced	with	NF-kB,	AP1	and	other	transcription	factors	contributing	to	T	
cell	activation,	CREB	can	bind	to	the	IL-27/EB13	promotor	region	as	well	as	promoting	IL-2	
production	 and	 proliferation	 (144).	 CREB	 is	 required	 for	 IL-27	 production,	 whereas	 other	
transcription	factors	downstream	of	TCR	stimulation	are	dispensable	(208).	Therefore	CREB,	
produced	 in	 response	 to	 TCR	 stimulation	 and	 PKA	 signalling,	 has	 both	 stimulatory	 and	
inhibitory	effects.		
	
Although	a	direct	 link	between	adenosine	 receptor	 signalling	 and	 IL-27	production	has	not	
been	explored,	PGE2	,	which	also	acts	to	elevate	intracellular	cAMP,	has	been	shown	to	directly	
influence	IL-27	production	via	CREB	(144,	150).	Furthermore,	an	association	between	elevated	











to	 add	 the	 inhibitory	 Y505	 phosphorylation	 to	 Lck,	 inhibiting	 TCR	 signalling,	 however	 the	
effects	 of	 A2aR	 engagement	 on	 Lck	 phosphotype	 have	 not	 been	 conclusively	 demonstrated	
(204,	209,	210).		
	



















































Since	 IL-27	 signalling	 promotes	 expression	 of	 a	 module	 of	 genes	 including	 IL-10	 and	 CIR	
expression,	 either	 adenosine	 or	 PGE2	 signalling	 could	 feed	 into	 the	 expression	 of	 multiple	





Taken	 together,	 these	 data	 suggest	 that	 Adenosine	 signalling	 through	 A2a	 receptors	 could	
inhibit	 T	 cells	 through	 multiple	 pathways,	 and	 further	 molecular	 studies	 are	 required	 to	
elucidate	 its	 exact	 effects.	 Furthermore,	 the	 effects	 of	 other	 adenosine	 receptors	 could	
antagonise	or	synergise	with	A2aR	signalling,	and	the	balance	of	adenosine	receptor	expression	

















expression	 is	 associated	with	negative	outcomes	 in	HNSCC,	NSCLC,	 ovarian,	 prostate,	 renal,	









The	mainstay	of	 cancer	 therapy	still	 consists	of	 surgical	excision	or	de-bulking,	 followed	by	
treatment	of	residual	disease	with	chemotherapy	or	radiotherapy,	aimed	at	the	non-specific	
destruction	of	rapidly	dividing	cells	(213).	Such	therapies	are	successful	in	destroying	cancer	








The	 term	 targeted	 therapies	 refers	 to	 the	use	of	agents	which	block	pathways	known	 to	be	





















cancer	 cell	 populations	 is	 immunotherapy,	 the	 concept	 of	 pharmacologically	 encouraging	
cancer	killing	by	immune	cells	(174).	The	use	of	immunotherapy	to	treat	patients	with	cancer	
has	seen	a	rapid	increase	in	study	over	the	last	15	years,	and	several	single	and	dual	therapy	






To	 determine	 why	 this	 occurred,	 the	 immune	 character	 of	 individual	 tumours	 must	 be	
characterised.	 Tumours	 are	 hugely	 complex	 in	 terms	 of	 their	 immune	 infiltrate,	 and	 the	
character	 and	 location	 of	 tumour	 immune	 cells	 has	 been	 shown	 to	 be	 a	 better	 indicator	 of	
prognosis	than	traditional	tumour	grading	in	several	cancer	types	(119).	In	particular,	studies	
of	 different	 cancers	 revealed	 that	 the	 presence	 of	 a	 CD8+	 T	 cell	 infiltrate	 is	more	 strongly	
associated	 than	 any	other	 cell	 type,	with	prognosis	 and	 response	 to	 immunotherapy	 (119).	
These	 findings	 have	 led	 to	 a	 classification	 known	 as	 the	 immunoscore,	 which	 categorises	







other	 forms	 of	 suppression.	 Altered-Immunosuppressed	 tumours	 express	 intermediate	
numbers	of	CD8+	TILs,	and	soluble	mediators	such	as	 IL-10	and	TGFb,	and	suppressive	cell	
populations	such	as	CD4+	Tregs	and	MDSC	also	contribute	to	immunosuppression	alongside	





insufficient	 at	 the	 TDLN	 (119).	 Therefore	 in	 Cold	 tumours	 and	 some	 Excluded	 tumours,	
inhibition	 of	 priming	 and	 infiltration	 into	 the	 tumour	 is	 a	 key	 limiting	 step	 in	 anti-tumour	





penetrating	 the	 tumour,	 and	 then	 potentiates	 their	 function	 once	 inside.	 Conversely,	
immunotherapy	for	hot	tumours	is	based	predominantly	on	modulation	of	TIL	function	through	





















Altered-Excluded	 and	 Altered-Immunosuppressed	 immunoscores	 are	 assigned	 to	 tumours	
which	have	CD8+TILs	(here,	labelled	CT	cells).	However,	in	Excluded	and	Immunosuppressed	
tumours,	a	complex	combination	of	immunosuppressive	(IM)	immune	cells	and	soluble	factors	
synergise	 with	 co-inhibitory	 receptor	 expression	 to	 suppress	 CD8+	 TIL	 cytotoxic	 function.	
Hence	 improving	 the	 priming	 and	 infiltration	 of	 CD8+	 TILs	 into	 Immunosuppressed	 or	
Excluded	tumours	is	beneficial,	to	change	the	quality	of	the	infiltrate	towards	an	inflammatory,	
anti-tumour	 type	 (119).	 Excluded	 tumours	 are	 differentiated	 from	 immunosuppressed	
tumours,	because	they	have	fewer	CD8+	TILs	,		
	



















tumour	 vaccines.	 However,	 vaccines	 produced	 limited	 clinical	 benefit	 in	 cancer	 for	 several	
reasons.	 Firstly,	 it	 is	 difficult	 to	 identify	 Tumour	 Associated	 Antigen	 in	many	 cancers,	 and	
therefore	to	determine	which	antigens	to	use	in	vaccines	(176).	Computational	strategies	are	
currently	 being	 utilised	 to	 determine	which	 antigens	 are	 presented	 by	 tumours	 on	MHC	 I,	
however	it	is	likely	that	epitopes	presented	on	MHC	II	to	activate	CD4+	T	cell	help	would	also	
need	 to	 be	 included	 in	 vaccines	 (215).	 Furthermore,	 tumours	 quickly	 downregulate	 the	
expression	of	antigens	contained	within	tumour	vaccines,	and	assume	a	TME	lacking	in	damage	
signals	and	replete	with	immunoinhibitory	signalling,	which	renders	DCs	unable	to	take	up	and	
present	 vaccine	 antigen	 in	 an	 immunogenic	 context	 at	 the	 TDLN	 (105).	 Therefore,	 tumour	
vaccines	have	key	limitations.		
	
Many	 new	 approaches	 focus	 on	 the	 selection	 of	 specific	 chemotherapy	 and	 radiotherapy	
designed	to	increase	damage	signalling	within	the	tumour	and	render	it	more	immunogenic,	
without	destroying	immune	cells.	In	this	respect	the	tumour	itself	acts	as	a	source	of	antigen	





















ATT	 (218).	 Key	 advances	 have	 occurred	 in	 the	 field	 of	 ATT	when	 improved	methods	were	






Vectors	encoding	an	engineered	T	cell	 receptor	with	specificity	 to	a	 chosen	 tumour-specific	
antigen	 can	 be	 expressed	 in	 T	 cells	 before	 ATT.	 These	 cells	 recognise	 the	 desired	 antigen	
presented	by	tumours	on	MHC	molecules,	however	tumours	are	adept	at	downregulating	MHC	
to	avoid	expressing	antigens	to	which	the	TCR	is	specific	(217).	Alternatively,	Chimeric	Antigen	
Receptors	 (CARs)	 can	 be	 generated.	 These	 receptors	 possess	 an	 antibody-like	 extracellular	









T	 cells	 require	 MHC	 to	 respond	 to	 antigen	 presentation	 and	 can	 therefore	 respond	 to	
















stimulating	 the	production	of	 chemokines	which	 recruit	T	 cells	 (220).	 In	addition,	 although	
anti-angiogenic	therapies	have	produced	limited	benefit	as	single	agents,	the	use	of	drugs	such	





























incidences	 of	 toxicity	 involve	 immune	 mediated	 colitis,	 and	 cutaneous	 inflammation,	 are	
potentially	fatal,	and	result	in	discontinuation	of	therapy	(117,	221,	222).	However,	pre-clinical	
data	suggests	that	blockade	of	other	CIRs	could	provide	clinical	benefit	in	cancer	and	that	other	
CIRs	 could	 be	 targeted	 with	 lower	 incidences	 of	 autoimmune	 side	 effects	 (119).	 TIM3	
antagonists	have	shown	great	promise	in	rescuing	tumours	which	acquired	resistance	to	anti-
PD-1	blockade	in	a	murine	model	of	lung	adenocarcinoma	(115).	Since	TIM3	is	expressed	at	
higher	 levels	 amongst	 TILs	 when	 compared	 with	 PBMC,	 current	 studies	 suggest	 that	 anti-
TIM3mAb	 can	be	 administered	with	minimal	 toxicity	 (134).	 LAG-3	 is	 another	CIR,	which	 is	
important	in	CD4+	Treg	function	and	anti-LAG3	mAb	are	in	current	clinical	trials	(223).	Other	







blocking	 IDO	 signalling	 in	 combination	 with	 PD-1	 blockade	 in	 melanoma	 did	 not	 produce	
improved	 results	 over	 anti-PD-1	 monotherapy.	 However,	 this	 approach	 might	 not	 be	
appropriate	 for	 melanomas	 which,	 as	 hot	 tumours,	 are	 regulated	 primarily	 by	 immune	
checkpoints.	 Therefore,	 trials	 of	 these	 MDSC	 inhibitors	 in	 tumours	 with	 a	 more	 complex	
immune	 landscape	could	provide	synergistic	 improvements	 in	anti-tumour	 immunity	(119).	
Indeed,	depletion	of	MDSCs	results	in	tumour	shrinkage	in	head	and	neck	cancers,	a	tumour	
rich	in	MDSC	populations,	when	combined	with	checkpoint	blockade	(119).	TIM3	blockade	has	
been	 shown	 to	 reduce	 MDSC	 numbers	 at	 tumour	 sites,	 and	 could	 be	 another	 approach	 to	
reducing	 MDSC	 activity	 (134).	 Another	 approach	 to	 immunotherapy	 involves	 depletion	 of	
regulatory	CD4+	T	cells,	although	this	is	difficult	to	achieve	in	human	patients	without	depleting	








At	 present,	 there	 are	 two	 key	 approaches	 to	 pharmacologically	 block	 adenosine	 signalling	





the	B16F10	melanoma	model	 (183,	225).	More	 recently,	A2aR	blockade	has	been	shown	 to	




cancers	with	more	 complex	 immunoscores	 (201).	 At	 present,	 only	 one	 human	 clinical	 trial	
utilising	A2aR	antagonists	as	a	single	agent	or	combined	with	anti-PD-L1	mAb,	has	released	




















Certain	 immunotherapies	 can	 block	 tolerance	mechanisms	which	 are	 necessary	 for	 normal	
immune	homeostasis,	but	are	subverted	by	cancer	to	avoid	immune	attack.	Therefore,	blocking	
these	tolerance	pathways	and	activating	the	immune	system	to	treat	cancer	can	be	associated	
with	 significant	 toxicity	 which	 is	 difficult	 to	 manage	 clinically	 (117,	 221,	 222,	 229).	 The	
identification	of	drug	targets	which	are	selectively	upregulated	in	tumours,	and	which	are	less	





Adenosine	 is	 an	 ideal	 candidate	 for	 tumour-specific	 immunotherapy,	 since	 its	production	 is	







of	 gut	 microbiota	 as	 prognostic	 markers	 for	 response	 to	 immunotherapy.	 Treatment	 with	






TME	 generated	 by	 solid	 tumours,	 such	 that	 they	 exert	 effective	 cytotoxic	 anti-tumour	
responses,	whilst	also	generating	a	memory	pool	(139).	Anti-cancer	immune	memory	would	
theoretically	 equip	 patients	 with	 the	 ability	 to	 prevent	 cancer	 recurrence	 and	 eradicate	
Introduction	
	 105	
minimal	 residual	 disease,	 without	 further	 treatment	 (12,	 45,	 230).	 However,	 the	 effect	 of	
tumour-derived	inhibitory	signals	on	memory	T	cell	development	has	not	been	well	studied.	In	







after	 entry	 into	 the	 tumour	 microenvironment	 (TME).	 Tumour-suppression	 of	 CD8+	 TILs’	




















transfer	 is	 used.	 Murine	 Renal	 Carcinoma	 (Renca)	 cell	 lines,	 express	 HA	 antigen	 from	 the	













































































antibody	 staining	 for	 CD8+	 T	 cells	 expressing	 Thy1.2	 (68).	 These	 data	 indicate	 that	 even	
without	ATT,	RencaHA	tumours	possess	CD8+	Tumour	Infiltrating	Lymphocytes	(TILs)	(Figure	












same	 starting	 Clone	 4	 T	 cell	 population,	 allowing	 the	 identification	 of	 differences	 in	 T	 cell	
effector	function	which	are	induced	by	the	TME	(77).		
	
1.7.3 Clone	 4	 T	 cells	 lose	 their	 cytotoxic	 function	 after	 transfer	 into	 RencaHA	
tumours	
Previous	work	in	the	RencaHA	model	used	microscopy	to	demonstrate	that	Clone	4	CTL	primed	





live	 cell	 imaging.	Two	parameters	of	 immune	synapse	 stability	were	assessed	based	on	 cell	










which	 could	 have	 resulted	 in	 suppression	 of	 the	 cytotoxic	 ability	 of	 adoptively	 transferred	
Clone	4	TILs.	Expression	of	the	co-inhibitory	receptor	PD-1	is	elevated	amongst	Clone	4	TILs	in	
the	Renca	HA	model	when	compared	with	CTL	primed	in	vitro	(44,	154).	Work	performed	in	




















Tregs	 isolated	 from	RencaHA	 tumours	do	not	produce	 IL-10	or	TGF-β,	which	 are	 canonical	







Further	 study	 demonstrated	 that	 both	 CD4+FOXP3+	 pTregs	 and	 CD4+FOXP3-	 Tr1	 cells	
extracted	 from	RencaHA	 tumours	 express	 the	 adenosine	 producing	 ectoenzymes	CD39	 and	
CD73,	 indicating	that	they	are	capable	of	producing	adenosine	(Figure	15C)(154).	Renca	HA	
tumour	cells	do	not	express	CD39	or	CD73,	thus	CD4+	Tregs	are	a	key	source	of	adenosine-
producing	 enzymes	 in	 our	 model	 (235).	 Several	 groups	 have	 shown	 that	 CD39	 and	 CD73	
expression	correlates	with	poor	prognosis	 in	animal	 tumour	models	and	 in	cancer	patients.	
Furthermore,	knockdown	or	blockade	of	inhibitory	A2a	adenosine	receptors	improves	control	
of	 tumour	growth	 in	 a	CD8+	T	 cell	 dependent	manner	 (236-238).	 In	our	model,	 the	 ex	 vivo	
suppression	of	CTL	proliferation	that	occurred	in	the	presence	of	CD4+	Tregs	extracted	from	
RencaHA	tumours	was	abolished	in	the	presence	of	the	specific	A2aR	antagonist	ZM241385	













ELISA	 for	 TGFb.	 N	 =	 10	mice	 over	 two	 experiments.	Mean	 +/-	 SEM	 shown.	 (B)	 Cells	 were	
incubated	with	PMA/Ionomycin	and	Golgi	plug	for	3	hours,	fixed,	permeabilised	and	stained	
using	 anti-IL-10	mAb.	 Representative	 flow	 cytometric	 data	 are	 shown.	 N	 =	 15	mice	 over	 3	
experiments.	(C)	Cells	were	fixed,	permeabilised	and	stained	with	anti-FOXP3,	anti-CD39	and	
anti-CD73	 antibodies.	 Representative	 flow	 cytometric	 data	 are	 shown.	 N	 =	 15	mice	 over	 3	
experiments.	(D)	Cells	were	FACS	sorted	according	to	their	expression	of	CD4	and	CD25	before	
being	co-cultured	with	naïve	CD8+	Clone	4	T	cells	in	the	presence	of	irradiated	mature	dendritic	
cells	 and	KdHA	peptide.	 The	A2a	 adenosine	 receptor	 antagonist	 ZM241385	was	 added	 to	 a	
subset	of	cells.	Cells	were	cultured	for	3	days	and	3H-Thymidine	was	added	for	the	last	8h	of	

















Therefore,	 in	Chapter	3,	 effector	 cytokine	production	and	 co-inhibitory	 receptor	 expression	
were	also	compared	between	Clone	4	TILs	and	CTL,	using	flow	cytometry.	In	addition,	the	host’s	
endogenous	 Thy1.2+	 CD8+	 TIL	 population	 was	 characterised	 for	 the	 first	 time.	 We	





Chapter	 4	 aimed	 to	 demonstrate	 the	 importance	 of	 A2a	 Adenosine	 Receptor	 signalling	 in	
suppressing	anti-tumour	immunity	within	RencaHA	tumours	in	vivo.	To	achieve	this,	specific	
A2aR-Antagonist	was	administered	systemically	to	tumour	bearing	mice,	and	tumour	growth	





TIM3	directly	 improved	 the	killing	 function	of	adoptively	 transferred	Thy1.1+	Clone	4	TILs.	














immunotherapy	 in	 the	RencaHA	model.	 It	 identifies	a	combination	 immunotherapy	strategy	
using	both	A2aR	antagonism	and	TIM3	blockade,	and	determines	some	mechanisms	by	which	
these	 two	 signalling	 pathways	 could	 synergise	 to	 inhibit	 CD8+	 T	 cell	 effector	 function	 and	








































Animal	 Services	 Unit	 (239).	 Mice	 were	 genotyped	 using	 blood	 samples	 harvested	 in	 blood	
buffer	 from	 the	 tail	 vein.	Blood	 samples	were	 stained	using	 anti-mouse	Vb8.1	 (eBioscience,	









tumours	 reached	 5	mm	 in	 either	 direction.	Mice	were	 grouped	 for	 treatment	 by	 randomly	
assigning	 a	 numeric	 identification	 to	 each	mouse.	 For	 adoptive	 transfer	 experiments,	 mice	
received	3.5	to	5	x	106	Clone	4	CD8+	T	cells,	primed	using	kdHA	peptide	(as	detailed	in	2.4.1)	
and	transferred	i.v.	in	PBS	on	day	5	after	activation.	For	in	vivo	immunotherapy	experiments,	
control	mice	 received	100	µl	 vehicle	 (15%	DMSO,	15%	Cremophore	EL,	 70%	PBS)	+/-	100	
µg/mouse	 isotype	control	 (Rat	 IgG2a,	2A3,	BioXcell	 InVivoMAb)(240).	Additional	batches	of	





























PenStrep	 (Gibco),	 0.04%	 b-Mercapto	 Ethanol	 (Gibco).	 Selective	 antibiotics	 were	 added	 for	
tumour	cell	 culture	as	 indicated.	Complete	medium	+	 IL-2	was	generated	by	supplementing	
with	 50	 U/ml	 recombinant	 human	 IL-2	 (National	 Institute	 of	 Health/NCI	 BRB	 Preclinical	























































PenStrep	(Gibco),	1%	MEM	None	Essential	Amino	Acids	 (Gibco).	For	 long	 term	culture,	300	




























mCherry	 or	 hCD58	 expressing	 plasmids	 (RencaWTmCherry,	 RencaHAmCherry,	




RencamCherryHA	 or	 RencamCherryWT	 tumour	 cells	were	 transfected	with	 plasmids	 (containing	
both	 a	 hygromycin	 resistance	 gene	 and	 the	 gene	 encoding	 GCAMP6s)	 using	 lipofectamine	
(Invitrogen)	and	following	the	manufacturer’s	protocol	for	adherent	cells.	Cells	containing	the	
























interest	 conjugated	 to	 GFP	 or	mCherry.	 Plasmids	 expressing	GFP-conjugated	 proteins	were	
generated	 using	 cloning	 (as	 detailed	 in	 2.5).	 25	 µl	 chloroquine	 was	 added	 directly	 to	 the	
phoenix	cell	plate	and	the	plate	placed	at	37°C	until	other	solutions	were	prepared.		
	
Then,	 the	 following	solutions	were	generated	 from	sterile	 filtered	reagents	 to	make	enough	
volume	 for	1	phoenix	plate	Solution	A:	2	µl	 1M	NaOH,	500	µl	Hepes	Buffered	Saline	 (HBS).	
Solution	B:	500	µl	dH20,	5	µl	of	plasmid	at	>3000	ng/µl	DNA.	To	solution	B,	62	µL	2M	CaCl2	was	
added	dropwise	to	produce	a	visible	precipitate.	Solution	B	is	was	then	added	to	Solution	A	by	
running	 dropwise	 whilst	 rapidly	 mixing	 the	 solution	 using	 a	 stripette	 gun.	 The	 resultant	
mixture	is	added	directly	to	the	phoenix	plate	which	has	been	incubating	with	chloroquine.		
	
Phoenix	 cells	 produce	 gag-pol,	 and	 envelope	 protein	 for	 ecotropic	 retrovirus,	 releasing	 the	











plated	 into	 a	 fresh,	 flat	bottomed	24	well	plate	 (Corning).	 8	µg/ml	protamine	 sulphate	was	
added	to	each	well,	the	24	well	plate	was	sealed	using	parafilm	and	centrifuged	at	200	xg	for	2	















































































































signalling	 intermediate	of	 interest.	This	 insert	was	placed	 into	a	digested	plasmid	backbone	
containing	pGC-eGFP.	Concentrations	of	vector	and	insert	were	determined	after	each	step	by	
running	1	µl	of	product	on	an	agarose	gel	containing	EtBr.	To	generate	hCD2TIM3	constructs,	


























































ERS	 6FE	 confocal	 system	 (Perkin-Elmer),	 a	 fluorescent	 microscope	 (LeicaDM16000)	 and	 a	
CSU22	 Spinning	 Disc	 (Yokogawa)	 and	 ‘Volocity’	 Image	 Acquisition	 Programme.	 40x	





lamellae	 and	 translocation	 (Chapter	 5,	 Figure	 35).	 GFP	 images	 were	 visualized	 using	 a	





The	 IncuCyteä	 Live	Cell	 analysis	 system	and	 IncuCyteä	 ZOOM	software	 (Essen	Bioscience)	





































































2.8.4.1 In	 situ	 staining	 of	 T	 cells	 on	 Coverslips	 using	 Phalloidin,	 Celltrace	 reagents	 and	
Antibodies		
15	mm	circular	coverslips	were	washed	in	10%	Sodium	Dodecyl	Sulphate	(SDS)	for	10	minutes	














µl	 of	 4%	paraformaldehyde	was	 added	directly	 onto	 the	T	 cells	without	 aspirating	 imaging	
















being	 washed	 3	 times	 in	 PBS	 and	 mounted.	 For	 PhosphoLck	 staining,	 the	 protocol	 was	
performed	as	above	except	the	fixation	step	was	performed	using	1x	Phosflow	cytofix	buffer	
(BD),	warmed	 to	 37°C	 for	 at	 least	 half	 an	 hour	 before	 use.	 Fixation	was	 carried	 out	 for	 15	
minutes	at	4°C.	Cells	were	washed	as	above	and	placed	into	200	µl	1x	BD	Phosflow	Perm	Buffer	
2,	pre-chilled	to	-20°C.	Coverslips	were	kept	on	ice	for	30	minutes	and	then	washed	3	times	in	
PBS	 1%	w/v	BSA.	 Antibodies	were	 added	 in	 1x	 BD	 Phosflow	Perm	Buffer	 2	 at	 the	 desired	















Celltrace	 (Thermofisher)	 reagents	 were	 resuspended	 in	 DMSO	 according	 to	 manufacturer	
protocols.	Clone	4	T	cells	were	washed	in	an	excess	of	PBS	before	being	resuspended	in	PBS	at	

























pelleted	 and	 resuspended	 in	 100	 µl	 FACS	 buffer	 per	 tube	 with	 antibody	 at	 the	 required	
concentration	(Table	2).	Cells	were	incubated	for	30	minutes	at	4°C.	Antibody	concentration	
was	 determined	 by	 titration	 using	 5	 concentrations	 centred	 around	 the	 manufacturer’s	







Cells	 were	 stained	 for	 extracellular	 markers	 as	 above.	 However	 instead	 of	 fixation	 in	 1%	
paraformaldehyde	for	storage,	cells	were	fixed	in	4%	paraformaldehyde	for	20	minutes	at	room	




















reached	 -20°C.	The	exact	perm	buffer	 to	be	used	depends	on	 the	chosen	phosflow	antibody	
panel.	After	staining	for	extracellular	markers,	instead	of	being	fixed	in	1%	paraformaldehyde	
for	analysis,	cells	were	centrifuged	at	250	xg	for	5	minutes	and	all	supernatant	removed	to	<50	
µl	 in	each	 tube.	Cells	were	 fixed	 in	100	µl	phosflow	cytofix	 from	 the	37°C	aliquot,	 vortexed	
briefly	 and	 incubated	 for	15	minutes	 at	 4°C.	Tubes	were	 topped	up	with	1	ml	 FACS	buffer,	
centrifuged	 and	 washed	 twice	 in	 1	 ml	 FACS	 buffer.	 After	 each	 centrifugation	 step,	 all	
supernatant	 was	 removed	 to	 <50	 µl	 and	 the	 tube	 vortexed	 to	 resuspend	 well.	 Cells	 were	
resuspended	 in	 1	ml	 perm	buffer	 per	 tube	 at	 -20	 degrees,	 vortexed	 and	 kept	 on	 ice	 for	 30	
minutes.	Tubes	were	centrifuged	and	resuspended	in	antibodies	made	up	in	50	µl	per	tube	of	










provided	by	 the	Gallimore	 laboratory,	Cardiff,	UK.	Hybridomas	were	cultured	 in	250	ml	cell	





and	 continuously	 stirred.	 33.3	 ml	 saturated	 ammonium	 sulphate	 was	 added	 per	 100	 ml	
supernatant,	 dropwise	 through	 a	 19G	 hypodermic	 needle	 attached	 to	 a	 50	ml	 syringe.	 The	
sample	was	incubated	overnight	at	4°C	with	continuous	stirring.	The	sample	was	centrifuged	
at	10000	xg,	 for	30	minutes	at	4°C.	The	supernatant	was	removed	and	saved.	Antibody	was	
harvested	 from	 the	 pellet	 by	 resuspending	 the	 pellet	 in	 PBS	 at	 1/5	 of	 the	 starting	 volume,	
avoiding	generating	bubbles.	The	protein	concentration	was	determined	using	a	BSA	Assay	Kit	












FACS	 tubes	 (Corning).	 100	µl	 10x	 complement	 stock	was	added	on	 top	of	 cells	 in	 complete	
medium	along	with	2	µg	per	tube	of	commercial	antiCD8mAb	or	the	combination	of	two	in-
house	 prepared	 anti-CD8	 depleting	 antibodies	 (Table	 2).	 Hybridoma	 supernatant	 and	 the	
supernatant	extracted	part	way	through	ammonium	sulphate	precipitation	were	also	added	at	




















3x	 in	 PBS.	 Slides	 were	 dried	 in	 the	 area	 around	 the	 section	 and	 a	 border	marked	 using	 a	
hydrophobic	pen	(ImmEdge).	Sections	were	blocked	with	2.5%	horse	serum	(Vector)	for	30	






























Therefore,	 we	 employed	 n	 =	 14	 mice	 per	 group	 over	 several	 experiments.	 For	 disease	





Samples	were	 compared	using	 independent	 sample	 t-tests	 for	 two	 sample	 comparisons.	 To	
determine	the	effect	of	one	or	more	independent	variables	on	one	dependent	variable	across	
>2	groups,	One	way	and	Two-way	ANOVA	were	used	(SPSS	statistics).	To	investigate	the	effect	
of	 one	 or	 two	 independent	 variables	 on	 >1	 dependent	 variable,	 One-way	 and	 Two-way	
MANOVA	were	used.	Tukey’s	post-hoc	test	was	used	for	multiple	comparisons	unless	Holm-
































Multivariate	 Analysis	 of	 Covariance	 (MANCOVA)	was	 performed	 to	 determine	 the	 effect	 of	
various	 parameters	 which	 could	 confound	 the	 analysis	 of	 growth	 and	 survival,	 such	 as	














































occurred	 in	 6/6	mice	 after	 depletion.	Mice	were	 required	 to	 spend	 6-10	 days	 in	 remission	
before	 depletion	 was	 performed.	 Based	 on	 an	 average	 of	 relapse	 times	 from	 previous	
experiments,	 the	 maximum	 percentage	 of	 tumours	 that	 would	 be	 expected	 to	 relapse	






Fluorescence	 Minus	 One	 control	 samples.	 Boolean	 gating	 tool	 was	 used	 to	 determine	 all	
possible	 combinations	 of	 expression	 of	 certain	 markers.	 Combination	 expression	 was	











PCA	 was	 then	 performed	 using	 R	 studio	 and	 the	 packages	 ‘FactoMineR’	 and	 ‘Factoextra’.	










Clone		 Fluorophore	 Application	 Manufacturer	 Dilution	
CD8a	 53-6.7	 FITC	 FC	 BD	Bioscience	 1/100	
CD8b	 53-6.7	 PeCy7	 FC	 Biolegend	 1/200	
CD4	 CKI1.5	 AF700	 FC	 Biolegend	 1/100	
CD39	 24DMSI	 PerCP-Cy5.5	 FC	 eBioscience	 1/100	
CD73	 T111.8	 BV605	 FC	 Biolegend	 1/100	
TIM3	 B8.2C1.2	 PE	 FC	 Biolegend	 1/100	
TIGIT	 1G9	 APC	 FC	 Biolegend	 1/100	
LAG3	 C9B7W	 Pe-Cy7	 FC	 eBioscience	 1/200	
PD1	 29F.1A12	 BV785	 FC	 Biolegend	 1/200	
TCRb	 H57-597	 AF647	 FC	 Biolegend	 1/200	
CD62L	 MEL-14	 PE	 FC	 Biolegend	 1/100	
CD44	 IM7	 PerCP-Cy5.5	 FC	 Biolegend	 1/100	
CD69	 H1.2F3	 BV605	 FC	 BD	Bioscience	 1/100	
CD103a	 2E7	 PE-Dazzle	 FC	 Biolegend	 1/50	
Thy1.1	 OX7	 FITC	 FC	 BD	Bioscience	 1/100	
Thy1.1	 OX7	 PerCP-Cy5.5	 FC	 Biolegend	 1/100	
TIM3	 RMT-23	 BV605	 FC	 Biolegend	 1/100	
Ceacam-1	 CC1	 APC	 FC	 Biolegend	 1/100	
IL-2	 JE56-5H4	 BV711	 FC	 Biolegend	 1/40	
IFNg	 XMG1.2	 PeDazzle	 FC	 Biolegend	 1/200	
IL-10	 JES5-16E3	
	
PE	 FC	 BD	Bioscience	 1/20	
Galectin-9	 RG9-35	 BV421	 FC	 BD	Bioscience	 1/100	
ICAM-1	
(CD54)	
YN1/1.7.4	 FITC	 FC	 Biolegend	 1/100	
Total	Lck	 MOL171	 PE	 FC,	IF	 BD	Bioscience	 1/5	
Lck	p505	 4/Lck-505	 AF605	 FC,	IF	 BD	Phosflow	 1/5	
Lck	p418	 K48-37	 AF488	 FC,	IF	 BD	Phosflow	 1/5	
PKCq	 T538		 na	 IF	 CST	 1/50	(in	situ	stain)	
LAT	 Polyclonal	 na	 IF	 CST	 1/100	(in	situ	stain)	










H+L	 AF405	 IF	(2°)	 Life	Technologies	 1:1000	










































































CD8a	 53-6.7	 na	 IHC	(1°)	 Biolegend	 1:500	
Isotype	 for	
CD8a	IHC	




H+L	 AF594	 IHC	(2°)	 Thermofisher	 1:2000	
Anti-Foxp3	 FJK-16s	 na	 IHC	(1°)	 Thermofisher	 1:100	
CD90.1	
(Thy1.1)	











Studies	 using	 the	 murine	 RencaHA	 tumour	 model	 have	 shown	 that	 when	 in	 vitro	 primed	
Thy1.1+	Clone	4	CTL	are	adoptively	transferred	into	RencaHA	tumour-bearing	mice,	Clone	4	
TILs	recovered	from	the	tumour	are	unable	to	directly	lyse	tumour	cell	targets	ex	vivo.	These	
findings	 suggest	 that	 a	 loss	 of	 cytotoxic	 function	 amongst	 Clone	 4	 TILs	 occurs	 within	 the	










both	 IL-2	and	 IFNg	 together.	As	 the	 immune	response	wanes,	 IL-10	producing	CD8+	T	cells	
dampen	inflammatory	responses	in	their	environment	(92,	250).	These	IL-10-producing	CD8+	
T	 cells	 are	 found	 at	 high	 numbers	 within	 tumours	 and	 can	 represent	 either	 a	 transient	
suppressed	 phenotype	 or	 a	more	 stable	 CD8+	Treg	 fate	 (151,	 251).	 Therefore,	 in	 RencaHA	
tumour	bearing	mice,	endogenous	Thy1.2+	CD8+	TILs	could	also	inhibit	adoptively	transferred	


















Previous	studies	 in	our	 laboratory	used	a	Widefield	microscope	system	to	 image	killing	of	a	
monolayer	of	fluorescent	RencaHA	tumour	cells	by	HA-specific	Clone	4	cytotoxic	T	lymphocytes	
(CTL)	 and	 TILs	 (76,	 77).	 The	Widefield	 killing	 assay	 indicated	 that	 the	 rate	 of	 cytolysis	 of	
tumour	cell	targets	by	TILs	was	reduced	when	compared	with	in	vitro	primed	Clone	4	CTL	(10%	
kill/hour	 CTL,	 4%	 kill/hour	 TILs)	 (76,	 77).	 However,	 there	 are	 limitations	 to	 the	 use	 of	
Widefield	killing	assays	in	that	only	three	conditions	can	be	analysed	simultaneously,	and	the	














Unpulsed	RencamCherryWT	cells	were	used	as	 controls.	Analysis	of	 red	 fluorescent	 target	 cell	













































cells	 falling	 into	 other	 categories.	 After	 stimulation,	 63%	 of	 CTL	 expressed	 IL-2/IFNg	
concurrently,	 and	 only	 8%	 produced	 IL-10	 or	 none	 of	 the	 cytokines	 tested.	 Before	
PMA/Ionomycin,	 38%	 of	 Thy1.1+	 Clone	 4	 TILs	 expressed	 no	 cytokines,	 or	 combinations	
including	IL-10,	however,	this	dropped	to	24%	after	stimulation.	52%	of	Clone	4	TILs	produced	




phenotype	 of	 the	 host’s	 Thy1.2+	 endogenous	 CD8+	 TILs.	 	 Over	 50%	 of	 endogenous	 TILs	
produced	IL-10	or	none	of	the	cytokines	tested	before	PMA/ionomycin,	whether	or	not	ATT	
was	administered	 to	 the	 tumour.	However,	 after	 stimulation,	only	14%	of	 endogenous	TILs	
produced	both	IL-2	and	IFNg,	but	25%	of	endogenous	TILs	from	ATT	tumours	produced	both	



















































































































































The	 data	 showed	 that	 the	 percentage	 of	 Clone	 4	 CTL	 expressing	 IL-10	 and	 TIM3	 was	
















extracellular	markers,	 fixed,	permeabilised	and	stained	 for	 intracellular	cytokines.	Data	was	
analysed	using	flow	cytometry.	(B)	shows	%	expression	and	(C)	shows	MFI	of	IL-2,	Ceacam-1,	
IL-10,	 TIM3,	 PD-1	 and	 IFNg	 calculated	 as	mean	 +/-	 SEM	 and	 compared	 using	 paired	 t-test	


































compared	 with	 TIM3-	 populations.	 In	 addition,	 the	 percentage	 of	 IL-10	 expressing	 cells	
increased	 amongst	 endogenous	 TIM3+	 TILs	 after	 PMA/Ionomycin,	 indicating	 that	 they	 are	





















received	 ATT,	 or	 Endogenous	 TILs	 from	 mice	 with	 no	 ATT	 were	 stained	 for	 intracellular	
cytokines	straight	after	harvesting	(pre)	or	after	4h	of	 incubation	with	PMA,	 Ionomycin	and	














and	 Brefeldin-A	 for	 4h	 and	 stained	 for	 IL-10	 expression.	 Data	 was	 acquired	 using	 flow	














































RencaHA	model	may	 also	 be	 able	 to	 produce	 adenosine,	 and	 suppress	 naïve	 Clone	 4	T	 cell	
proliferation	via	A2aRs.		
	
To	 address	 this	 hypothesis,	 flow	 cytometric	 analyses	 were	 used	 to	 show	 that	 in	 RencaHA	
tumours,	 CD8+	TILs	 do	 express	 the	 adenosine	 producing	 enzymes	 CD39	 and	 CD73	 (Figure	


















blocking	 both	 IL-10R	 and	 A2a	 adenosine	 receptors	 concurrently.	 Although	 co-blockade	 of	















































































improve	 the	 effector	 function	 of	 Clone	4	TILs	within	 the	RencaHA	TME.	To	 investigate	 this	
hypothesis,	 the	 cytokine	 profiles	 of	 populations	 of	 Thy1.1+	 Clone	 4	 TILs	 and	 Thy1.2+	






4	TIL	 immune	synapse	 is	morphologically	unstable	when	compared	with	 immune	synapses	
formed	by	Clone	4	CTL	(76,	77).	However,	 intracellular	staining	showed	that	although	some	












the	 TME,	 inducing	 a	 greater	 proportion	 of	 endogenous	 CD8+	TILs	 to	 become	 effectors	 and	
reducing	the	proportion	of	IL-10	producing	endogenous	TILs.	This	could	be	due	to	the	fact	that	
although	the	killing	function	of	Clone	4	TILs	is	impaired,	they	still	produce	some	IFNg	which	


















primed	 in	 vitro	 and	 transduced	 to	 overexpress	 NFIL3.	 It	 was	 clear	 that	 NFIL3	 expression	
promoted	 both	 TIM3	 and	 IL-10	 production	 and	 repressed	 IL-2	 production.	 Interestingly,	
preliminary	overexpression	of	NFIL3	amongst	CD4+	T	cells	was	associated	with	reduced	IL-2	
and	 elevated	 IL-10	 production,	 however	 it	 was	 not	 associated	 with	 alterations	 in	 TIM3	





















Alternatively,	 TIM3	 could	 have	 been	 engaged	 by	 ligands	 in	 cell	 culture	 (256).	 Ceacam-1	 is	
expressed	at	low	levels	amongst	Clone	4	CTL	in	in	vitro	cultures	and	this	could	engage	TIM3	
(Figure	20).	Furthermore,	phosphatidylserine	produced	from	apoptotic	cells	is	also	a	ligand	for	
TIM3.	 If	TIM3	was	engaged	by	 inhibitory	 ligands,	 then	the	mechanism	by	which	 it	mediates	

















when	 compared	 with	 isotype	 controls.	 Although	 blockade	 of	 TIM3	 and	 reduced	 IL-10	











(115,	 116,	 121,	 122).	 Cytokine	 production	 suggested	 that	 TILs	 in	 the	 RencaHA	 model	 are	
tumour-suppressed,	 so	 combinations	 of	 CIR	 expression	 were	 compared	 with	 confirm	 this	
hypothesis.	 Clone	 4	 and	 endogenous	 CD8+	 TILs	 were	 more	 likely	 to	 express	 CIRs	 in	
combination,	whereas	in	vitro	primed	cells	tended	to	express	single	CIRs.	The	percentages	of	
suppressed	 cells	 expressing	 PD-1	 and	 TIM3	 together	 is	 similar	 between	 Clone	 4	 TILs	 and	
endogenous	 TILs.	 However,	 the	 fact	 that	 a	 greater	 proportion	 of	 endogenous	 CD8+	 TILs	
expressed	none	of	the	CIRs	tested	(and	in	earlier	experiments	produced	none	of	the	cytokines	
assayed)	when	compared	with	Clone	4	TILs	suggests	 that	more	endogenous	TILs	are	either	
naïve	 or	 tolerant.	 Therefore,	 the	 total	 proportion	 of	 effector	 cells	 is	 greater	 amongst	 ATT	
Thy1.1+	Clone	4	TILs.		
	
























presence	of	anti-IL-10RmAb	alone	 in	 cultures	of	naïve	Clone	4	T	cells	was	able	 to	 suppress	
proliferation	when	TILs	were	not	present.	Such	contradicting	results	have	also	been	reported	
by	 several	 groups,	 suggesting	 that	 IL-10R	 signalling	 acts	 in	 a	 context	 dependent	 manner.	
Although	IL-10	is	classically	considered	to	be	immunosuppressive,	it	may	support	naïve	T	cell	




Since	 IL-10	blockade	only	produced	 a	 very	modest	 improvement	 in	T	 cell	 proliferation,	we	
considered	other	CD8+	TIL-derived	factors	which	could	suppress	Clone	4	T	cells.	Previous	work	
has	 shown	 that	 CD4+	 TILs	 from	 the	 RencaHA	 model	 express	 CD39	 and	 CD73,	 and	 we	
demonstrated	that	endogenous	CD8+	TILs	also	express	these	adenosine	producing	enzymes.	












producing	 CD8+	 T	 regulatory	 cells	 suppress	 in	 a	 TGFb	 dependent	 and	 contact-dependent	








Clone	 4	 TILs,	 reducing	 their	 effector	 potential	 (218,	 219,	 258,	 259).	 RencaHA	 tumour-










function,	 and	 their	 ability	 to	 control	 RencaHA	 tumour	 growth	 in	 vivo,	 mice	 were	 treated	
systemically	with	A2aR-Antagonist	and	the	following	parameters	assessed:	(i)	tumour	growth,	






4.2.1.1 Treatment	 with	 A2aR-Antagonist	 is	 associated	 with	 reduced	 RencaHA	 tumour	
growth		
To	 test	 the	 hypothesis	 that	 Adenosine	 Receptor	 signalling	 is	 a	 crucially	 important	 pathway	




Antagonist	 treated	 mice	 when	 compared	 with	 vehicle	 treated	 controls.	 However,	 although	





4.2.1.2 Expression	 of	 Single	 Co-Inhibitory	 Receptors	 amongst	 TILs	 is	 not	 significantly	
altered	by	A2aR	blockade		
Several	 studies	 have	 shown	 that	 when	 one	 immunomodulatory	 pathway	 is	 blocked	 by	
immunotherapy,	 other	 immunosuppressive	 pathways	 are	 initiated	 within	 tumours.	 For	
example,	 NK	 cells	 are	 known	 to	 upregulate	 Co-inhibitory	 receptors	 (CIRs)	 when	 IL-12	 is	
administered	 as	 immunotherapy	 (201,	 261).	 Therefore,	 we	 hypothesised	 that	 endogenous	
CD8+	TILs	could	upregulate	CIRs	when	RencaHA	tumour-bearing	mice	are	treated	with	A2aR	
antagonist	(191,	238).	CIR	signalling	could	thus	inhibit	CD8+	TILs,	reducing	the	efficacy	of	A2aR	
blockade.	 To	 test	 this	 hypothesis,	 CD4+	 and	 CD8+	 TILs	 from	 A2aR-Antagonist	 treated	 and	
untreated	tumour-bearing	mice	(Figure	26)	were	analysed	using	flow	cytometry	to	assess	their	
levels	 of	 expression	 of	 the	 CIRs	 TIM3,	 TIGIT,	 LAG3	 and	 PD-1.	 Expression	 of	 the	 adenosine	
producing	 enzymes	 CD39	 and	 CD73	 was	 also	 quantified,	 because	 another	 mechanism	 of	






















and	 further	 treatment	was	 administered	 every	 other	 day.	Mice	were	 culled	when	 tumours	






















































analysed	 individually.	 However,	 recent	 studies	 suggest	 that	 expression	 of	 several	 CIRs	
concurrently	is	required	to	indicate	that	CD8+	TILs	have	a	tumour-suppressed	genotype	(121,	
122,	 135).	 Therefore,	 Principal	 Component	 Analysis	 (PCA)	 was	 used	 to	 determine	 if	 the	
combinations	of	CIRs	expressed	by	TILs	was	altered	after	A2aR	blockade.	PCA	is	a	method	for	




the	 analysis,	making	 153	 variables	 in	 total.	 Data	 are	 transformed	 such	 that	 individuals	 (i.e.	
tumour-bearing	 mice)	 are	 spread	 or	 clustered	 along	 linear	 axes	 known	 as	 Principal	
Components	 (PC).	 Numbered	 arrows	 indicate	 the	 variables	 which	 are	 different	 between	
individuals,	causing	this	spread	or	clustering.	Different	permutations	are	generated	along	PCs,	
until	100%	of	the	variation	within	the	data	set	has	been	accounted	for.	In	this	analysis,	a	cut	off	
of	 20	 variables	 was	 determined	 because	 only	 20	 variables	 made	 greater	 than	 average	
contributions	to	the	PCA.	The	first	PC	(PC1)	generated	by	the	analysis	accounts	for	the	greatest	
proportion	of	variation	within	 the	data,	 in	 this	 instance	24.7%.	Subsequent	PCs	account	 for	
progressively	less	variation.	In	this	analysis,	the	first	4	PC	were	analysed	because	other	PC	had	
low	eigenvalues,	meaning	that	they	did	not	display	important	differences	between	individuals.	
































(red	dots)	are	 found	to	 the	 left.	The	variable	arrows	which	point	 to	 the	right	of	PC1,	where	
treated	tumours	cluster,	include	many	combinations	of	CIRs	which	comprise	TIM3	expression	
amongst	 CD8+	 TILs	 (p<0.001)	 (Supplementary	 Figure	 S4B).	 This	 finding	 suggests	 that	
increased	 expression	 of	 TIM3	 by	 CD8+	 TILs	 is	 a	 key	 variable	 which	 differentiates	 A2aR-
Antagonist-treated	 from	 control	 individuals.	 Negatively	 correlated	 with	 PC1,	 and	 therefore	
treatment,	is	a	lack	of	any	CIR	expression	amongst	CD8+	T	cells	(p<	0.001)(Figure	28A).	Overall,	
the	 variables	 that	 caused	 separation	 between	 A2aR-blocked	 tumours	 and	 control	 tumours	
represented	combinations	of	CIRs,	in	particular	combinations	that	included	TIM3.		
	
Together,	 the	 clustering	 of	 tumours	 along	 PC2	 suggested	 that	 the	 immunosuppressive	
mechanisms	 operating	within	 small,	 untreated	 tumours	 depend	 upon	 CIRs,	whereas	 larger	
untreated	 tumours	 express	 adenosine	 producing	 enzymes.	When	 tumours	 are	 treated	with	
A2aR-Antagonist,	this	switch	to	adenosine-mediated	suppression	appears	to	be	prevented,	and	








elevated	 in	 tumours	 of	 smaller	 sizes	 when	 compared	 with	 control	 tumours	 (Figure	 28B)3.	



























Analysis	 (PCA),	 along	 with	 tumour	volume	 as	 the	 final	 variable.	Each	 triangle	 or	 circle	
represents	an	individual	tumour	bearing	mouse.	Large	symbols	represent	the	average	position	
of	 a	 treated	 and	 control	 individual	 along	 PC1.	 Direction	 of	 the	 clustering	 of	 A2aR	 blocked	
tumours	on	a	biplot	of	PC1	and	PC2	is	shown	by	a	green	arrow.	The	top	20	of	the	154	variables	
contributing	 to	PC1	and	PC2	 are	 shown	as	 arrows	 labelled	numerically.	 A	 key	detailing	 the	
combinations	of	markers	represented	by	these	numbers	 is	shown	in	(Supplementary	Figure	
S4).	The	variable	representing	CD8+	T	cells	expressing	TIM3	 in	combination	with	any	other	






























and	 anti-TIM3mAb	 followed	 a	 similar	 growth	pattern	 in	 each	 of	 four	 separate	 experiments	
(Supplementary	Figure	S5).	Tumour	growth	was	divided	into	3	phases	for	analysis:	Phase	1	
was	defined	as	initial	tumour	growth	from	day	12	to	days	16-18;	in	Phase	2,	a	proportion	of	













occasions	 and	 treated	 (Tx)	 with	 A2aR-Antagonist,	 anti-TIM3mAb,	 or	 vehicle	 +	 isotype	 as	
control,	as	shown.	A	triphasic	growth	curve	was	produced.	In	Phase	1,	tumours	grew.	In	Phase	
2	and	3	tumours	regressed	and	then	either	remained	regressed	until	the	end	of	the	experiment	





































which	 relapsed	 were	 compared	 using	 Fisher's	 exact	 Boschloo	 test.	 (iii)	 Progression	 free	
survival	 (PFS)	 analysed	using	 Cox	 Proportional	 Hazards	 Regression	analysis.	Predictive	
treatments	 were	 C	 (p=0.033*)	 or	 D	 (p=0.005**).	 Treatments	 A	 and	 B	 did	not	




































(Methods	 Section	2.12.3)(Figure	30i).	R-values	 illustrated	 that	 tumours	 from	Group	D	mice	
(ATT	+	anti-TIM3mAb)	grew	the	slowest	of	all	groups	during	this	time5.	Tumours	from	Group	
C	mice	 (ATT	 +	 AR-Antagonist	 +	 anti-TIM3mAb)	 grew	 significantly	 slower	 than	 those	 from	
control	Group	A	mice	(ATT	alone)	or	Group	B	mice	(ATT	+	AR-antagonist).	Thus,	the	data	show	




The	main	 goal	 of	 any	 anti-cancer	 therapy	 is	 to	 achieve	 tumour	 regression	 and	 increase	 the	





















found	 to	 occur	 at	 any	 timepoint	 from	 day	 24	 (Figure	 29).	 To	 determine	 whether	 or	 not	






appears	 to	give	rise	 to	a	reduction	 in	 the	percentage	of	mice	with	relapsing	 tumour	growth	
when	compared	with	other	groups	(Figure	30ii).	
	
Another	key	aim	of	 cancer	 therapy	 is	 to	 try	 to	extend	 the	 time	before	 relapse	occurs.	Thus,	
Progression	Free	Survival	(PFS)	was	used	to	quantify	the	time	before	relapse	(i.e.	remission)	
amongst	tumour-bearing	mice.	This	period	of	PFS	was	defined	as	the	time	between	the	initial	
injection	 of	 tumour	 cells,	 and	 the	 tumour	 reaching	 a	 volume	 which	 exceeded	 the	
starting	volume.	 Cox	 Proportional	 Hazards	 Regression	analysis	 was	 used	 to	 compare	 PFS	
between	mice	(Figure	30iii).	PFS	was	included	as	the	dependent	variable,	and	the	analysis	was	
set	up	to	determine	whether	the	treatments	carried	out	within	Groups	A-D	significantly	affected	






variable	 that	significantly	 predicted	 PFS	was	 the	 Treatment	 Group.	 Treatment	 of	 tumour	
bearing	 mice	 with	 A2aR-Antagonist	 and	 anti-TIM3mAb	(Group	 C,	 p=0.033*)	 or	anti-
TIM3mAb	alone	(Group	D,	p	=	0.005**)	significantly	 influenced	PFS.	Whereas,	administering	




























To	compare	 the	effects	of	 treatment	on	 long	 term	tumour	growth,	 the	average	 final	 tumour	
volume	in	each	group	(at	time	of	culling	for	each	mouse)	was	calculated	as	a	ratio	of	the	final:	
initial	tumour	volume	(246,	248).	Amongst	Group	C	mice,	treatment	with	A2aR-Antagonist	and	
anti-TIM3mAb	 produced	 a	 significantly	 reduced	 final:	 initial	 tumour	 volume	 ratio	 when	
compared	 with	 Group	 A	 control	 mice.	 There	 were	 no	 other	 significant	 differences	 in	 final	
tumour	volume	(Figure	30iv).	This	finding	suggests	that	if	tumours	relapse	in	mice	treated	with	









disease	 (MRD)(226-228,	 264).	 To	 test	 whether	 or	 not	 Responder	 mice	 could	 mount	 anti-














to	 mice	 bearing	 RencaHA	 tumours.	 ATT	 Clone	 4	 T	 cells	 were	 not	 administered	 in	 this	
experiment,	 to	 enable	 the	 effects	 of	 A2aR	 blockade	 to	 be	 observed	 in	 the	 absence	 of	 other	
immunotherapies.	A2aR	antagonism	resulted	 in	partial	 control	of	 tumour	growth,	however,	
tumours	did	not	completely	regress.	Since	blockade	of	one	immunosuppressive	pathway	can	
select	 for	 the	 upregulation	 of	 others,	 PCA	 was	 used	 to	 determine	 if	 the	 expression	 of	
combinations	of	certain	CIRs	were	upregulated	after	 treatment	with	A2aR-Antagonist.	 (139,	
191,	194,	261).	Notably,	the	expression	of	combinations	of	CIRs	involving	TIM3	were	increased	






specific	 and	 occurs	 only	 at	 low	 levels	 in	 body	 sites	 outside	 of	 the	 tumour(188,	 190,	 266).	
Blocking	 TIM3	 and	 A2aRs	 as	 an	 immunotherapeutic	 combination	 should	 therefore	 be	
advantageous	because	neither	agent	is	likely	to	produce	off-target	effects	if	blocked	(103,	120,	
132,	 134).	 Furthermore,	 blocking	 TIM3	 with	 monoclonal	 antibodies	 has	 proved	 to	 be	 an	
effective	adjunct	to	other	cancer	immunotherapies,	including	anti-PD-1	blockade,	where	it	has	
been	 shown	 to	 rescue	 control	 of	 tumour	 growth	 amongst	 mice	 which	 relapse	 after	 initial	
therapy	(103).		
	
To	determine	 if	 control	 of	 tumour	 growth	was	better	when	TIM3	 and	A2aRs	were	blocked	






was	divided	 into	 three	phases	 for	 analysis:	Phase	1,	 initial	 growth;	Phase	2,	 regression	and	
relapse;	and	Phase	3,	final	volume.		
	
Different	 parameters	 of	 therapeutic	 benefit	 were	 measured	 at	 different	 stages	 of	 tumour	
growth.	 Although	 anti-TIM3mAb	 treatment	 was	 most	 effective	 at	 slowing	 initial	 tumour	
growth,	this	treatment	regimen	produced	the	greatest	risk	of	relapse.	Importantly,	the	addition	
of	 A2aR-blockade	 was	 required	 to	 prevent	 Relapse.	 Other	 studies	 also	 suggest	 that	 anti-
TIM3mAb	is	more	effective	as	an	adjunct	therapy	than	a	single	agent	(103).	Blocking	A2aRs	
together	 with	 TIM3	 in	 the	 presence	 of	 ATT	 increased	 the	 percentage	 of	 Responder	 mice	
experiencing	regression,	reduced	the	Hazard	Ratio	of	relapse,	and	also	produced	the	 lowest	
final:	 initial	 tumour	 volume	 ratio	 amongst	 relapsed	 tumours	 when	 compared	 with	 other	
groups.	 Therefore,	 taking	 all	 parameters	 into	 account,	 utilising	 A2aR-Antagonist	 and	 anti-
TIM3mAb	 concurrently	 produced	 the	 best	 control	 of	 RencaHA	 tumours	 across	 the	 entire	
disease	progression.	
	























Several	 studies	 suggest	 that	 the	 ability	 to	 resist	 relapse	 and	 rechallenge	 in	mouse	 tumour	





which	 tumours	were	 completely	 eradicated,	 because	 following	 further	 injections	 of	 tumour	
there	was	no	tumour	re-growth.	Injection	of	the	same	batch	of	cells	into	immunologically	naïve	
mice	 at	 the	 same	 time	 as	 other	mice	were	 rechallenged	 did	 result	 in	measurable	 tumours,	
indicating	 that	 the	 tumour	cells	used	 for	rechallenge	were	 functional	 (data	not	shown).	The	
effect	 of	 treatment	 with	 A2aR-Antagonist	 and	 anti-TIM3mAb	 on	 the	 development	 of	 anti-
tumour	immune	memory,	is	determined	using	experiments	in	Chapter	7.		
	






responders	 to	 anti-adenosine	 therapy,	 meaning	 that	 selecting	 patients	 to	 receive	 A2aR	
blockade	could	be	more	straightforward	when	compared	with	other	cancer	immunotherapies,	
such	as	anti-CTLA-4	and	anti-PD-1	mAbs,	for	which	biomarkers	of	response	are	lacking	(181,	







Chapter	5 Blockade	 of	 A2a	Adenosine	 Receptors	 and	 TIM3	 produces	



















































interactions	between	TIM3	and	 target	 cells.	However,	 no	 significant	 improvement	 in	killing	
occurred	after	 acute	 treatment	with	blocking	anti-TIM3mAb	 (Figure	32).	To	 investigate	 the	
effect	of	TIM3	signalling	over	several	days	in	the	tumour,	killing	by	Clone	4	TILs	was	quantified	
after	single	treatment	with	anti-TIM3mAb	over	ten	days	in	vivo.	However,	anti-TIM3mAb	did	








determine	 whether	 or	 not	 A2aR	 blockade	 was	 effective	 without	 blockade	 of	 TIM3,	 single	
treatment	with	A2aR-Antagonist	was	also	administered.	However,	treatment	with	only	A2aR-









were	harvested	on	day	16	and	placed	 in	microscope-based	 cytotoxicity	 assays.	 (A)	Tumour	



































































































alone	 (Figure	 33A).	 Although	 this	 result	 was	 not	 significant,	 it	 did	 further	 support	 the	
hypothesis	that	blockade	of	A2aRs	promoted	upregulation	of	TIM3	amongst	CD8+TILs	within	
RencaHA	tumours	(Chapter	4,	Figure	28).	When	tumour-bearing	mice	were	treated	with	both	
A2aR-Antagonist	 and	 anti-TIM3mAb,	 the	 percentage	 of	 TIM3+PD1+	 CD8+	 TILs	 was	
significantly	 lower	 than	TIM3+PD-1+	TILs	 from	control	mice,	 suggesting	 that	blocking	both	







RencaHA	 tumour-bearing	 BALB/c	 mice	 received	 ATT	 of	 Clone	 4	 T	 cells	 and	 treated	 with	
combinations	 of	 A2aR	 Antagonist	 and	 anti-TIM3mAb.	 All	 CD8+	 TILs	 were	 harvested	 and	
stained	with	antibodies	to	quantify	levels	of	expression	of	PD-1	and	TIM3	using	flow	cytometry.	
(A)	 Percentage	 expression	 of	 markers	 was	 compared	 using	 MANOVA	 of	 arcsine	 sqrt	
transformed	data.	Each	point	=	1	tumour,	N	=	3	experiments	in	total.	Tumours	analysed	on	the	
same	day	are	paired	for	comparison.	(B	and	C)	Fold	change	in	the	MFI	of	each	marker	when	
compared	 to	 the	 Fluorescence	 minus	 one	 (FMO)	 control	 from	 that	 day	 of	 analysis	 were	











































allowing	cytotoxic	granules	 to	move	 through	 the	cSMAC	area,	 this	 ring	does	not	need	 to	be	









shown	 that	 activated	Clone	4	CTL	 localise	F-tractin	 from	 the	 centre	 to	 the	periphery	of	 the	
immune	synapse	upon	target	cell	contact	and	maintain	a	peripheral	ring	for	180s	during	killing.	
Conversely,	Clone	4	TILs	fail	to	maintain	a	peripheral	actin	ring	after	exposure	to	the	TME.	The	
observation	 that,	 amongst	 TILs,	 immune	 synapse	 stability	 and	 cytotoxicity	 is	 also	 deficient	
supports	the	Actin	Maintenance	model	which	suggests	that	poor	actin	ring	maintenance	results	






































A2aR-Antagonist	 plus	 anti-TIM3mAb-	 treated	mice	 relative	 to	 control	 TILs	 (p=	 0.02*	 180s;	












immune	 synapse	 formation	 between	TILs	 or	 in	 vitro	 primed	Clone	 4	 CTL	 and	KdHA-pulsed	
Renca	tumour	cell	targets	was	imaged	ex	vivo	using	confocal	microscopy.	Analyses	to	quantify	
accumulation	 of	 f-tractin	 were	 performed	 in	 >30	 cell	 couples	 per	 condition,	 across	 2-4	
experiments.	 (A)	 The	 percentage	 of	 couples	 which	 expressed	 a	 peripheral	 actin	 ring	 was	
quantified.	 (B	 &	 C)	 Growth	 curves	 of	 the	 tumours	 used	 for	 analyses	 are	 shown	 with	
representative	controls	if	injected	in	the	same	experiment.	Arrows	indicate	the	timing	of	ATT.	
(D)	 Percentage	 of	 couples	 with	 peripheral	 F-tractin	 accumulation	 was	 compared	 between	















































































immune	 synapse	 stability	 resulting	 in	 failed	 target-cell	 killing.	 As	 peripheral	 actin	 ring	







4	T	cell.	However	Off-L	differ	 from	functional	projections	which	are	directed	at	 the	 immune	
synapse	 to	 ensure	 its	 stability,	 because	 they	 are	 directed	 away	 from	 the	 target	 cell.	 Earlier	






translocation	 is	 reduced,	 indicating	 that	 A2aR-antagonist	 treated	 TILs	 form	 more	 stable	
immune	synapses	when	compared	with	control	TILs.	Survival	without	Off-L	and	translocation	
are	both	restored	further	towards	control	levels	if	both	A2aR-Antagonist	and	anti-TIM3mAb	
are	 used	 to	 treat	 tumour	 bearing	 mice	 (Figure	 35A-D).	 These	 data	 suggest	 that	 double	
treatment	of	tumour	bearing	mice	with	A2aR-Antagonist	and	anti-TIM3mAb	improved	the	ex	
vivo	 stability	 of	 immune	 synapses	 between	 TILs	 and	 tumour	 cell	 targets.	 Immune	 synapse	


















with	 combinations	 of	 A2aR-Antagonist	 and	 anti-TIM3mAb.	 Measures	 of	 immune	 synapse	
stability	were	quantified	using	confocal	imaging	of	immune	synapse	formation	between	in	vitro	
primed	Clone	4	CTL	or	harvested	Clone	4	TILs,	and	KdHA	pulsed	Renca	tumour	cell	targets	ex	
vivo.	 Formation	 of	 Off-Interface	 Lamellae	 (Off-L,	 membrane	 projections	which	 are	 directed	
away	from	the	immune	synapse)	was	quantified.	(Ai)	Representative	images	are	shown	from	a	
single	 experiment.	 The	 interface	 of	 the	 immune	 synapse	 is	 illustrated	 in	 red	 before	 off-L	
formation	(Aii)	one	off-L	is	shown	circled	in	blue.	(B)	Survival	until	formation	of	first	Off-L	was	
























5.2.2.3 The	 Actin	 Clearance	Model:	 treatment	with	 A2aR	 and	 TIM3	 blockade	 improves	
Actin	Clearance	from	the	cSMAC		
The	second	model,	explaining	how	actin	regulation	is	linked	to	the	delivery	of	cytolytic	granules	
by	CD8+	T	 cells,	 is	 the	Actin	Clearance	model.	The	Actin	Clearance	model	 suggests	 that	 the	
purpose	 of	 peripheral	 actin	 ring	 formation	 is	 not	 immune	 synapse	 stability,	 but	 rather	
clearance	of	actin	so	that	cytotoxic	granules	can	pass	through	the	cSMAC	(71).	In	this	model,	
provided	actin	clearance	 is	achieved,	 the	actin	does	not	need	to	 form	a	complete	and	stable	
peripheral	 ring.	 Therefore,	 any	 actin	 pattern	 which	 does	 not	 cover	 the	 cSMAC	 would	 be	
permissive	to	killing.	According	to	the	Actin	Clearance	model,	Clone	4	TILs	from	A2aR	and	TIM3	
blocked	 tumours	 should	 clear	 actin	more	 efficiently	 from	 the	 cSMAC	when	 compared	with	
controls	because	they	have	better	ex	vivo	cytotoxic	ability.	To	compare	actin	clearance	between	
Clone	 4	 TILs	 from	A2aR-antagonist	 and	 anti-TIM3mAb-treated	 and	 control	 tumour-bearing	
mice,	 the	 existing	 data	 were	 re-analysed	 so	 that	 couples	 expressing	 either	 peripheral	 or	
asymmetric	actin	were	categorised	as	having	‘Permissive’	actin	patterning	which	did	not	cover	




Treatment	 of	 tumour	 bearing	mice	 with	 A2aR-Antagonist	 and	 anti-TIM3mAb	 resulted	 in	 a	
reduction	 in	 the	 percentage	 of	 TILs	 expressing	 obstructive	 actin	 between	 0	 and	 60s	when	
compared	 with	 control	 TILs.	 Treatment	 of	 mice	 with	 A2aR-Antagonist	 alone	 reduced	
obstructive	actin	to	a	lesser	degree.	These	reductions	were	not	statistically	significant.		
	
At	 later	 timepoints,	 between	 60-120s,	 A2aR-Antagonist	 plus	 anti-TIM3mAb	 treated	 mice	
exhibited	lower	obstructive	actin	when	compared	with	TILs	from	control	mice,	but	TILs	from	












A2aR-Antagonist	 and	 anti-TIM3mAb	 also	 produced	 elevated	 numbers	 of	 TILs	 exhibiting	
permissive	 actin	 patterning	 when	 compared	 with	 control	 TILs.	 However,	 the	 increase	 in	
permissive	actin	which	resulted	from	treatment	with	A2aR-Antagonist	with	and	without	anti-
TIM3mAb	 was	 not	 significant	 when	 compared	 with	 TILs,	 and	 permissive	 actin	 remained	
significantly	 lower	 than	 CTL	 at	 all	 timepoints	 in	 both	 treated	 conditions,	 meaning	 that	










immune	 synapse	 formation	 between	TILs	 or	 in	 vitro	 primed	Clone	 4	 CTL	 and	KdHA-pulsed	
Renca	 tumour	 cell	 targets	 was	 imaged	 ex	 vivo	 using	 confocal	 microscopy.	 Analyses	 of	 the	
accumulation	 of	 f-tractin	 were	 performed	 in	 >30	 cell	 couples	 per	 condition,	 across	 2-4	
experiments.	 The	 percentage	 of	 couples	which	 expressed	 (A	 &	 C)	 obstructive	 and	 (B	 &	 D)	



























Figure	 36	 –	 Treatment	 with	 A2aR-Antagonist	 and	 Anti-TIM3mAb	 reduces	













































5.2.3 Blockade	 of	 A2aRs	 and	 TIM3	 improves	 the	 number	 of	 CD8+	 TILs	 and	
reduces	the	number	of	FOXP3+	Tregs	within	RencaHA	tumours	
We	hypothesised	that	the	improved	control	of	tumour	growth	observed	when	A2aRs	and	TIM3	
























RencaHA	 tumour-bearing	BALB/c	mice	were	given	ATT	of	Clone	4	T	 cells	 and	 treated	with	
combinations	of	A2aR-Antagonist	and	anti-TIM3mAb.	Size-matched	tumours	from	treated	and	
control	 mice	 were	 sectioned	 and	 immunohistochemical	 staining	 was	 performed	 using	
antibodies	specific	to	CD8b,	Thy1.1	and	FOXP3.	Sections	were	fixed	and	imaged	using	confocal	
microscopy.	10	peripheral	and	10	central	areas	were	examined	across	sections	of	each	tumour	
to	 quantify	 the	 numbers	 of	 (A+B)	 total	 CD8+	 TILs	 and	 FOXP3+	 cells	 or	 (C+D)	 Endogenous	

























from	 A2aR-Antagonist	 and	 anti-TIM3mAb	 treated	 mice,	 with	 TILs	 from	 control	 mice.	
Treatment	 was	 administered	 using	 the	 same	 protocol	 which	 produced	 complete	 tumour	
regression	(as	detailed	in	Chapter	4).	TILs	were	harvested	16	days	after	tumour	injection,	to	
ensure	 that	 there	was	 sufficient	 tumour	mass	 from	which	 to	 extract	 them.	The	data	 clearly	
showed	 that	when	A2aR	and	TIM3	blockade	was	administered	 to	RencaHA	 tumour-bearing	











































treated	 mice,	 indicating	 that	 double	 treatment	 produces	 fewer	 suppressed	 CD8+	 TILs.	 An	
important	limitation	of	this	assay	is	that	therapeutic	anti-TIM3mAb	could	block	binding	of	the	
fluorescent	anti-TIM3mAb,	such	that	TIM3	positive	cells	could	not	be	detected	amongst	TILs	
from	mice	which	 received	double	blockade.	However,	 this	 is	 an	unlikely	 scenario,	 since	 the	
blocking	antibody	was	administered	48h	before	staining,	and	several	studies	suggest	 that	 it	














determines	 the	 stability	 of	 contacts	 between	 CD8+	 T	 cells	 and	 APCs.	 Clone	 4	 TILs	 exhibit	
shortened	peripheral	ring	maintenance	and	impaired	parameters	of	immune	synapse	stability	
when	compared	with	Clone	4	CTL.	By	blocking	PD-1	systemically	in	tumour	bearing	mice,	we	








A2aR-Antagonist	 alone.	 In	both	 instances,	 restoration	of	peripheral	 actin	 amongst	TILs	was	
partial	 when	 compared	 with	 control	 CTL.	 Although	 the	 improvement	 in	 peripheral	 actin	
accumulation	was	relatively	modest,	improvements	in	immune	synapse	stability,	which	reflect	
the	functional	effects	of	actin	ring	maintenance,	were	significant.	Importantly,	the	use	of	anti-
TIM3mAb	 and	 A2aR-blockade	 together	 produced	 synergistic	 benefit	 to	 immune	 synapse	
stability.		
	




A2aR-Antagonist	 and	Anti-TIM3mAb	 and	 TILs	 from	 control	mice,	 data	were	 re-analysed	 to	







this	was	 reduced	still	 further	amongst	TILs	 treated	with	A2aR-Antagonist	and	adjunct	anti-
TIM3mAb.	Other	studies	have	shown	that	0-60s	is	a	key	timepoint	during	which	granules	pass	
through	the	cSMAC,	therefore	although	the	levels	of	obstructive	actin	amongst	TILs	from	mice	









influx	 into	 the	 target	 cell	 (71).	 However,	 Renca	 tumour	 cells	 were	 found	 to	 perform	
spontaneous	 calcium	 flux	when	 not	 in-contact	with	 CTL,	 indicating	 that	 the	 Renca	 cell	 line	
cannot	be	used	as	targets	to	assess	lytic	hit	delivery	by	Clone	4	T	cells	(Data	not	shown).	Further	





The	 ex	 vivo	 assays	 that	were	 carried	 out	 to	 quantify	 cytotoxicity,	 CIR	 expression	 and	 actin	
regulation	by	Clone	4	TILs	revealed	that	treatment	of	tumour-bearing	mice	with	A2aR	and	TIM3	
blockade	resulted	 in	 improved	cytotoxic	effector	 function	amongst	CD8+	TILs.	However,	we	
hypothesised	 that	 synergy	 between	 improved	 CD8+	 TIL	 function	 and	 greater	 infiltrating	
numbers	of	CD8+	TILs	could	explain	the	durable	control	of	tumour	growth	that	is	observed	in	
mice	after	A2aR	and	TIM3	blockade.	Adenosine	signalling	is	known	to	affect	infiltration	of	TILs	
in	 models	 of	 mouse	 melanoma,	 whereby	 blockade	 of	 A2b	 receptors	 is	 associated	 with	 an	
increase	 in	the	percentage	of	CD8+	TILs	within	the	TME	(272).	Histological	sections	of	size-
matched	RencaHA	 tumours	 from	mice	given	ATT	of	Clone	4	T	 cells	 alone	 (Control)	or	with	
A2aR-Antagonist	 plus	 anti-TIM3mAb	 were	 assessed	 using	 immunohistochemistry.	 These	
analyses	revealed	that	the	only	significant	difference	between	treated	and	control	tumours	was	






and	Clone	4	TILs	was	elevated,	 leading	 to	an	 increase	 in	 the	overall	numbers	of	CD8+	TILs	





is	 likely	 that	 systemic	 blockade	 of	 these	 pathways	 provokes	 a	 generalised	 increase	 in	 pro-
inflammatory	signalling	within	the	TME.	This	could	cause	multiple	immune	cell	types	to	release	
chemoattractant	signals	which	attract	CD8+	T	cells.	Such	pro-inflammatory	mediators	could	
result	 in	 the	 reversal	 of	 CD4+	Tregs	back	 to	 a	Th1	phenotype,	which	 could	 account	 for	 the	




adenosine	 receptors,	 and	 blockade	 of	 CD73	 on	 endothelia	 has	 been	 shown	 to	 facilitate	
endothelial	 activation	 and	 upregulation	 of	 adhesion	 molecules	 which	 promote	 lymphocyte	
transmigration	 (273-275).	 Analyses	 to	 determine	 the	 mechanism	 by	 which	 adenosine	 and	
TIM3	signalling	affects	infiltration	are	the	focus	of	other	work	within	our	laboratory.		
	
Overall,	 the	 combination	 of	 A2aR-Antagonist	 plus	 anti-TIM3mAb	 was	 shown	 to	 improve	
several	measures	of	effector	function	amongst	adoptively	transferred	Clone	4	TILs	as	well	as	
endogenous	CD8+	TILs.	Therefore,	this	combination	of	immunotherapy	targets	both	infiltration	
































In	 section	 6.2.1,	 the	 effects	 of	 A2aR	 signalling	 on	 the	 above	 parameters	 are	 examined,	 and	







































concentrations	 could	 produce	 dose-dependent	 suppression	 of	 Clone	 4	 T	 cell	 proliferation.	
However,	Celltrace	Violet	can	only	detect	a	limited	number	of	population	divisions,	whereas	









Clone	 4	 cell	 proliferation	 when	 compared	 with	 vehicle-treated	 controls	 (p=0.01**)	 and	
interestingly,	 1	 µM	 NECA	 produced	 more	 suppression	 of	 proliferation	 than	 10	 µM.	 These	
findings	 suggested	 that	 lower	 concentrations	 of	 NECA	 could	 produce	 more	 profound	
suppression	of	Clone	4	T	cell	proliferation	than	higher	concentrations	in	some	contexts.	When	
100	µM	NECA	was	added	to	Clone	4	T	cells	at	0h	and	cells	harvested	at	72h,	proliferation	was	












of	 the	 specific	 A2aR-Antagonist	 ZM241385,	 and	 cells	 were	 then	 harvested	 at	 72h,	 the	
suppression	 of	 Clone	 4	 T	 cell	 proliferation	 achieved	 by	 both	 concentrations	 of	 NECA	 was	









a	 predominantly	 suppressive	 effect	 on	 CD8+	 T	 cells	 stimulated	 by	 anti-CD3/28	 mAb,	 and	






































































































































































Clone	 4	 T	 cells	 expressing	 TIM3,	 TIGIT,	 LAG3	 or	 PD1,	 when	 each	 marker	 was	 assessed	


















































on	 both	 stimulatory	 as	 well	 as	 inhibitory	 adenosine	 receptor	 subtypes.	 However,	 the	
predominant	adenosine	receptor	subtype	expressed	in	tumours	is	the	inhibitory	A2a	receptor.	



























in	 the	 presence	 of	 NECA	 but	 in	 the	 absence	 of	 IL-2	would	 result	 in	 greater	 suppression	 of	
cytotoxic	function,	IL-2	was	omitted	from	cell	culture.	However,	this	resulted	in	a	decrease	in	
both	the	overall	cell	viability	and	cytotoxicity	amongst	control	Clone	4	CTL	in	the	absence	of	IL-








conditions	are	 compared,	 and	One-way	ANOVA	 if	>2	conditions	are	 compared.	P-values	are	







































for	 actin	behaviour	 at	 the	CTL	 immune	 synapse	 in	order	 to	permit	 the	delivery	of	 cytolytic	
granules	to	target	cells	(Introduction,	Figure	43).	The	Actin	Maintenance	model	suggests	that	
formation	and	maintenance	of	 a	peripheral	 actin	 ring	 is	 required	 to	achieve	 stable	 immune	
synapses	between	CTL	and	target	cells.	The	Actin	Clearance	model	suggests	that	the	stability	of	
the	 immune	 synapse	 is	 less	 important	 than	 clearance	 of	 actin	 from	 the	 cSMAC	 to	 permit	





quantifying	 the	percentage	of	 cell	 couples	accumulating	F-tractin	at	 the	 immune	synapse	 in	
different	patterns	(as	shown	in	Introduction,	Figure	6	and	Chapter	5	Figures	34,	35	and	36).	
	
The	 Actin	 Maintenance	 Model:	 Addition	 of	 NECA	 to	 Clone	 4	 CTL	 in	 culture	 impairs	
peripheral	actin	ring	maintenance	and	immune	synapse	stability	
	
To	 test	 whether	 the	 requirements	 of	 the	 Actin	 Maintenance	 Model	 were	 disrupted	 by	













Earlier	 times	 of	 Off-L	 formation	 are	 indicative	 of	 immune	 synapse	 instability,	 hence	 Off-L	
formation	was	compared	using	a	Mantel-Cox	survival	analysis.	In	control	CTL,	77%	of	couples	
do	not	form	any	Off-L	within	the	coupling	period,	indicating	stable	contact	with	target	cells.	The	











higher	 levels	 of	 immunosuppressive	 A2aRs	 relative	 to	 immunostimulatory	 A1	 and	 A3	








Translocation	 of	 Clone	 4	 CTL	 away	 from	 the	 original	 site	 of	 immune	 synapse	 formation	 is	
another	measure	of	immune	synapse	instability.	Treatment	of	Clone	4	CTL	with	either	1	µM	or	
10	µM	NECA	resulted	in	increased	translocation	amongst	Clone	CTL	couples	when	compared	











compared	 with	 untreated	 control	 CTL.	 The	 presence	 of	 PGE2	 also	 results	 in	 increased	























































Therefore,	 we	 hypothesised	 that	 NECA-treated	 Clone	 4	 CTL	 could	 also	 fail	 to	 maintain	 a	































A2aR-Antagonist	 (ZM)	and	PGE2	as	 indicated	or	ATT	 into	RencaHA	 tumour-bearing	mice	 to	
generate	TILs.	Cells	were	harvested	and	immune	synapse	formation	between	TILs	or	in	vitro	



















































































































The	 results	 show	 that	 amongst	 TILs,	 the	 percentage	 of	 cell	 couples	 with	 early	 cofilin	



















The	 addition	 of	 specific	 A2aR-Antagonist	 to	 cell	 culture,	 in	 the	 presence	 of	 10	 µM	 NECA,	
restored	the	ability	of	Clone	4	CTL	to	accumulate	peripheral	cofilin	between	0-40s,	such	that	
the	 percentage	 of	 NECA	 plus	 A2aR-Antagonist-treated	 CTL	 which	 accumulated	 peripheral	
cofilin	was	not	significantly	lower	than	untreated	control	CTL	between	0-40s	(p=0.52).	At	later	
timepoints,	 after	 40s	 from	 immune	 synapse	 formation,	 peripheral	 cofilin	 accumulation	






accumulation	 to	begin	with.	However,	 the	 levels	 of	 decline	 appear	 to	be	 intermediate,	with	
peripheral	 cofilin	accumulation	 remaining	higher	 than	CTL,	but	 lower	 than	TILs.	Treatment	
with	A2aR-Antagonist	in	the	presence	of	NECA	results	in	restoration	of	the	peak	of	peripheral	
























































F-tractin	 and	 cofilin	 induced	 by	 NECA	 treatment	 are	 associated	 with	 significantly	 reduced	
immune	 synapse	 stability	 when	 compared	 with	 untreated	 CTL.	 Although,	 amongst	 cells	
cultured	with	NECA	plus	A2aR-Antagonist,	the	phenotype	of	F-tractin,	cofilin	and	Off-interface	








therefore	 hypothesised	 that	 the	 Actin	 Clearance	 model	 could	 perhaps	 better	 explain	 the	





















with	 NECA	 10	 µM	 plus	 A2aR-Antagonist	 did	 not	 lower	 obstructive	 actin,	 and	 actually	
significantly	 exacerbated	 obstructive	 actin	 patterning	 amongst	 CTL	 when	 compared	 with	












Treatment	 with	 10	 µM	 NECA	 plus	 A2aR-Antagonist	 resulted	 in	 significantly	 elevated	
permissive	actin	at	40-60s	when	compared	with	10	µM	NECA	alone	(p=0.05*).	Permissive	actin	
accumulation	amongst	TILs	was	not	significantly	different	to	10	µM	NECA-treated	CTL	at	any	


















































































































CTL	with	TIM3GFP.	However,	 overexpression	 did	 not	 guarantee	 that	 the	TIM3	 receptor	was	
engaged	by	any	ligand	in	cell	culture	(Chapter	3,	Figure	21).	
	





signalling	 through	the	TIM3	cytoplasmic	 tail.	As	 there	are	no	murine	 ligands	 to	hCD2,	TIM3	



















































used,	because	TIRF	 is	able	 to	detect	 the	presence	of	objects	within	20nM	of	 the	cell	 surface	
membrane	 (Figure	 48A).	 hCD2TIM3GFP	 was	 available	 for	 signalling	 at	 the	 cell	 surface	
membrane,	and	it	inserted	in	the	same	punctate	pattern	seen	with	unmodified	TIM3GFP.	This	












TIM3	cytoplasmic	tail,	 the	hCD2TIM3	construct	was	modified,	giving	 it	 the	ability	to	bind	to	
Ceacam-1	in	cis.	To	achieve	Ceacam-1	recruitment,	the	Immunoglobulin	(Ig)	domain	of	TIM3	
(which	is	the	Ceacam-1	binding	site	of	the	TIM3	molecule),	was	added	to	hCD2TIM3	(Figure	
47A	 &	 B).	 The	 resulting	 construct	 was	 named	 ‘hCD2TIM3Ig’.	 We	 hypothesised	 that	 the	 Ig	











6.2.2.3 Signalling	 through	 Chimeric	 TIM3	 and	 Ceacam-1	 does	 not	 affect	 the	 cytotoxic	
function	of	in	vitro	primed	Clone	4	CTL		
To	determine	whether	or	not	signalling	through	hCD2TIM3Ig	suppressed	the	killing	function	




There	were	 no	 significant	 differences	 in	 the	 cytotoxic	 abilities	 of	 cells	 expressing	 different	
hCD2TIM3Ig/Ceacam-1GFP	 construct	 combinations	 (Figure	 48C).	 To	 determine	 whether	
signalling	through	A2aRs,	Ceacam-1	and	hCD2TIM3Ig	together	within	Clone	4	CTL	suppressed	










to	 a	 coverslip	 coated	with	 Anti-CD3mAb	 and	 ICAM-1.	 Upon	 cell	 spreading,	 GFP	 signal	 was	
observed	within	20nm	of	the	cell	surface	membrane,	by	TIRF	microscopy	Early	(top)	and	late	







































bearing	mice	resulted	 in	 improved	ex	vivo	 cytotoxic	effector	 function	amongst	Clone	4	TILs.	
Therefore,	 it	 was	 decided	 to	 examine	 the	 TCR	 signalling	 events	 that	 could	 be	 inhibited	
downstream	of	A2aR	and	TIM3	engagement	in	order	to	suppress	Clone	4	CTL.	Previous	studies	
have	 suggested	 that	 A2aR	 engagement	 could	 inhibit	 TCR	 signalling	 within	 Clone	 4	 CTL	 by	
increasing	PKA	activity,	resulting	in	the	addition	of	inhibitory	phosphate	groups	at	Y505	of	Lck	
(205).	Whilst	A2aR	signalling	could	affect	Lck	phosphorylation,	TIM3	signalling	is	thought	to	
affect	 the	 spatiotemporal	 localisation	 of	 Lck	 at	 the	 immune	 synapse	 (54,	 55,	 285).	 Several	
studies	suggest	that	engagement	of	TIM3	by	inhibitory	ligands	causes	the	release	of	Bat-3	from	
the	TIM3	cytoplasmic	tail,	and	Bat-3	takes	with	it	a	pool	of	active	Lck.	Thus,	TIM3	engagement	

























6.2.3.2 The	 Spatiotemporal	 localisation	 of	 Lck	 cannot	 be	 determined	 amongst	 in	 vitro	
primed	Clone	4	CTL	using	Confocal	Microscopy		
















Lck	 is	present	within	CD8+	T	 cells	 in	 three	main	phosphorylated	 forms,	 and	 the	balance	of	
availability	 of	 these	 phosphotypes	 affects	 the	 potential	 for	 successful	 TCR	 signalling.	
Engagement	of	the	A2aR,	a	G-protein	coupled	receptor,	mediates	an	increase	in	intracellular	
cyclic	AMP,	increasing	the	activity	of	PKA,	and	subsequently	Csk	-	a	tyrosine	kinase	which	adds	




the	TIM3	cytoplasmic	 tail	and	with	 it	 removes	a	pool	of	Lck,	 reducing	 the	potential	 for	TCR	
signal	amplification	(54,	138).	Therefore,	A2aR	signalling	and	TIM3	signalling	could	synergise	































































































































































































using	confocal	microscopy.	 (A)	Celltrace	violet	 labelled	Clone	4	CTL	(blue)	and	 intracellular	
actin	stained	with	phalloidin	(green)	are	shown.	(B)	Celltrace-violet	labelled	Clone	4	CTL	(blue)	
were	 treated	 with	 pervanadate	 to	 induce	 phosphorylation	 of	 cellular	 tyrosine	 residues	


















vivo	 after	 recovery	 from	 the	 tumour	 (287,	 288).	 However,	 in	 vivo	 studies	 do	 not	 illustrate	
whether	blockade	was	acting	directly,	improving	Clone	4	T	cell	function	by	blocking	A2aRs	and	







6.3.1 The	 addition	 of	 Adenosine	 Receptor	 Agonists	 to	 cell	 culture	 suppresses	







was	 assessed	 using	 Celltrace	 Violet	 staining	 and	 3H-thymidine	 incorporation.	 The	 results	
showed	that	proliferation	of	naïve	Clone	4	T	cells	was	suppressed	in	the	presence	of	1	µM	NECA.		
	




be	 influenced	 by	 NECA,	 which	 could	 prevent	 quantification	 of	 the	 concentration	 of	 NECA	
required	to	suppress	CTL	directly.	Priming	using	KdHA	peptide,	which	is	the	method	usually	


















to	 limit	 proliferation,	 and	 it	 produced	 significant	 cytotoxicity	 amongst	 Clone	 4	 T	 cells,	
suggesting	that	suppression	of	proliferation	by	Adenosine	was	caused	by	cell	death	rather	than	
by	A2aR	dependent	 signalling	 (278,	289).	Therefore,	NECA	was	used	 in	 future	proliferation	
assays.		
	









ongoing	 analyses.	 Adding	 NECA	 to	 Clone	 4	 T	 cells	 did	 not	 produce	 significant	 suppression	









T	 cells	 (144,	 202).	 In	 a	 separate	 study,	 autocrine	 IL-27/IL-27R	 interactions	were	 shown	 to	
promote	expression	of	the	CIR	gene	module	in	CD8+	T	cells,	which	results	in	TIM3,	TIGIT,	LAG3,	



















Antagonist	 was	 included	 in	 cell	 culture,	 only	 the	 immunostimulatory	 A1	 and	 A3	 receptor	





other	 subtypes	 (1,	 14-18).	 Therefore,	 PGE2	 and	 TGFb,	 two	 factors	 which	 are	 known	 to	 be	
present	within	the	RencaHA	TME,	were	added	to	cell	culture	along	with	NECA.	We	postulated	











was	 used	 because	 cytotoxicity	 assays	 were	 executed	 in	 parallel	 with	 live	 cell	 imaging	
experiments,	 which	 required	 Clone	 4	 CTL	 to	 be	 transduced	 with	 GFP-tagged	 signalling	
intermediates.	Our	current	transduction	protocol	can	only	be	achieved	in	peptide-primed	cells.	
However,	 the	rapid	cell	division	generated	by	KdHA	peptide	results	 in	 IL-2	depletion	within	
cultures	of	Clone	4	CTL,	therefore	IL-2	supplementation	is	required.	IL-2	supplementation	can	
reduce	the	threshold	for	TCR	signalling	amongst	CTL,	and	can	allow	recovery	of	suppressed	








sufficient	 proliferation	 for	 uptake	 of	 GFP-tagged	 constructs	 after	 transduction	 for	 live	 cell	
imaging	experiments.		
	




T	 cells.	 The	 Actin	 maintenance	 model	 stipulates	 a	 requirement	 for	 peripheral	 actin	 ring	






Alternatively,	 the	 Actin	 Clearance	 model	 suggests	 that	 immune	 synapse	 stability	 is	 less	
important,	and	actin	clearance	 from	the	cSMAC	 is	 fundamental	 to	allow	the	delivery	of	 lytic	
granules	by	CTL	(71).	NECA-treated	cells,	which	are	capable	of	killing,	exhibit	permissive	and	
obstructive	actin	patterning	resembling	that	of	TILs,	which	cannot	kill	target	cells.	Therefore,	
neither	 the	 Actin	Maintenance	 nor	 Actin	 Clearance	models	 explain	 how	 actin	 distributions	
relate	to	CTL	killing	in	vitro	(71).		
	
PGE2	was	 also	 added	 to	 cell	 culture,	 to	 determine	 the	 effects	 of	 concurrent	 engagement	 of	
multiple	 pathways,	 which	 are	 found	 within	 RencaHA	 tumours,	 on	 Clone	 4	 T	 cell	 immune	
synapses.	The	effects	of	NECA	and	PGE2	appeared	to	be	redundant	rather	than	additive,	which	







quantity	 of	 surface	 expression	 of	 TIM3	 was	 variable	 between	 in	 vitro	 cultures,	 and	 TIM3	
expression	was	affected	by	the	method	of	priming	used	in	preliminary	studies	(Supplementary	
Figure	S8).	To	circumvent	the	problem	that	TIM3	is	not	consistently	expressed,	and	that	we	
could	 not	 engage	 TIM3	with	 any	 known	 ligand	 to	 confidently	 ensure	 inhibitory	 signalling,	







Recent	 studies	 published	 during	 the	 course	 of	 these	 experiments	 demonstrated	 that	
engagement	of	TIM3	by	either	of	its	inhibitory	ligands,	Galectin-9	or	Ceacam-1,	is	required	for	
TIM3	to	exert	an	inhibitory	function	(Figure	49)	(54,	138).	In	the	absence	of	these	ligands,	TIM3	
cytoplasmic	 tails	 bind	 Bat3,	 a	molecule	which	maintains	 a	 reservoir	 of	 Lck	 at	 the	 immune	
Does	engagement	of	A2a	Adenosine	Receptors	and	TIM3	expressed	on	Clone	4	T	cells	directly	affect	their	Function	in	vitro?	
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synapse	 and	 lowers	 the	 threshold	 for	 TCR	 signalling	 (54).	 Therefore,	 it	 is	 possible	 that	
hCD2TIM3	was	functioning,	but	that	it	was	exerting	the	stimulatory	effect	of	TIM3	by	recruiting	
Bat3	and	Lck	to	the	immune	synapse	(54).	A	Ceacam-1	binding	immunoglobulin	domain	was	
added	to	 the	hCD2TIM3	molecule	 to	allow	it	 to	pull	 in	Ceacam-1	expressed	by	Clone	4	CTL.	
Ceacam-1	can	interact	with	TIM3	on	the	same	cell	in	cis,	causing	Bat3	to	be	released	from	the	







use	 of	 a	 Ceacam-1mCherry	 vector	 would	 allow	 colocalization	 of	 hCD2TIM3IgGFP	 and	 Ceacam-
1mCherry	to	be	examined	using	TIRF	microscopy.		
	

















for	 72h	 without	 IL-2	 in	 the	 presence	 of	 combinations	 of	 NECA,	 the	 specific	 A2aR	 agonist	
Does	engagement	of	A2a	Adenosine	Receptors	and	TIM3	expressed	on	Clone	4	T	cells	directly	affect	their	Function	in	vitro?	
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CGS2680	 and	 PGE2.	 Phosphorylated	 Lck	 was	 assessed	 using	 phosflow	 cytometry	 and	
proliferation	was	also	quantified	using	 loss	of	Celltrace	Violet	 fluorescence.	Treatment	with	
NECA,	CGS2680	or	PGE2	resulted	in	suppression	of	Clone	4	cell	proliferation,	and	a	reduction	in	






















































Additionally,	 the	 effects	 of	 TIM3	 on	 Clone	 4	 T	 cell	 cytotoxic	 effector	 function	 could	 be	
determined	using	the	RencaHA	spheroid	system.	TIM3GFP	can	be	overexpressed	amongst	Clone	
4	 T	 cells	 and	 these	 cells	 used	 for	 spheroid	 infiltration.	 Renca	 tumour	 cells	 could	 also	 be	
transfected	 with	 Ceacam-1	 or	 Galectin-9	 to	 ensure	 that	 spheroids	 express	 TIM3	 ligands.	











anti-tumour	 immune	memory	 T	 cells.	Memory	 CD8+	 T	 cells	 are	 able	 to	 rapidly	 respond	 to	
secondary	 tumour	antigen,	and	can	 therefore	prevent	 regrowth	of	minimal	 residual	disease	
(MRD).	MRD	describes	microscopic	populations	of	cancer	cells	that	remain	after	macroscopic	
tumour	lesions	have	been	eradicated.	It	is	now	accepted	that	MRD	is	an	important	mediator	of	










an	 important	 question.	 Characterisation	 of	 the	 specific	memory	 T	 cell	 subsets	 that	 prevent	
relapse	within	murine	tumour	models	could	allow	T	cells	to	be	diverted	to	achieve	a	specific	
memory	phenotype	before	being	administered	as	part	of	adoptive	transfer	therapies	which	aim	
to	 prevent	 relapse	 in	 human	 cancer	 patients	 (230,	 296).	 However	 studies	 disagree	 about	
whether	CD8+	T	 cells	which	possess	 a	T	Central	memory	 (TCM)	phenotype	or	 a	T	Effector	













able	 to	 resist	 rechallenge	 with	 further	 injections	 of	 tumour	 cells,	 these	 mice	 were	 termed	
‘Responders’.	 In	 some	 mice,	 tumours	 did	 relapse,	 and	 these	 mice	 were	 termed	 ‘Non-
Responders’.	It	was	hypothesised	that	by	comparing	populations	of	memory	T	cells	present	in	
the	 tissues	 of	 Responder	 and	 Non-Responder	mice,	 it	 would	 be	 possible	 to	 identify	 which	
memory	subsets	are	present	within	tumour-bearing	mice	that	resist	tumour	relapse.		
	
Memory	 T	 cell	 subsets	 were	 also	 compared	 between	 mice	 receiving	 different	 treatment	
regimens	as	shown	in	Table	6.	As	systemic	blockade	of	A2aRs	and	TIM3	has	been	shown	to	
restore	the	ex	vivo	cytotoxic	effector	function	of	Clone	4	TILs,	it	was	postulated	that	treatment	
















a. Responders	 (in	 which	 tumours	 regressed	 and	 did	 not	 relapse)	 and	 Non-	
responders	(in	which	tumours	regressed	and	then	relapsed).		
	








RencaHA	 tumour-bearing	 BALB/c	 mice	 were	 given	 ATT	 of	 Clone	 4	 T	 cells	 and	 treated	 as	
follows:	Group	A	-	Vehicle	and	Isotype	control;	Group	B	-	A2aR-Antagonist;	Group	C	-	A2aR-















































memory	 T	 cells	 than	 those	 which	 respond	 with	 low	 affinity	 (12,	 45).	 Therefore,	 it	 was	





































The	 data	 showed	 that	 following	 immunisation,	 Thy1.1+	 cells	 could	 not	 be	 identified	 in	 the	
spleen	or	TDLN	of	any	treatment	group	(Figure	54).	However,	Thy1.1+	cells	were	isolated	from	
the	 tumours	 of	 Non-responders	 of	 mice	 in	 all	 treatment	 groups	 except	 Group	 B	 (A2aR-
Antagonist	alone)	after	immunisation.	As	before,	Group	C	and	D	mice	possessed	the	greatest	
numbers	 of	 Thy1.1+	 Clone	 4	 TILs.	 These	 data	 supported	 findings	 from	 pre-immunisation,	
suggesting	that	treatment	with	anti-TIM3mAb	favoured	the	persistance	of	Thy1.1+	TILs	within	
the	TME	(300).	Interestingly,	whereas	Thy1.1+	cells	were	not	present	within	the	TME	of	Group	
A	 (Control,	ATT	only)	mice	prior	 to	 immunisation,	Thy1.1+	cells	 could	be	 isolated	 from	 the	
tumours	of	Group	A	mice	after	immunisation	(Figure	54).		
	
Overall,	 these	 experiments	 suggested	 that	 at	 42-56	 days	 from	 tumour	 injection,	 Thy1.1+	
memory	 T	 cells	 could	 not	 be	 identified	within	 the	 secondary	 lymphoid	 tissues	 of	 RencaHA	


































were	 immunised	with	 influenza	A/PR/8/H1N1.	 CD8+	T	 cells	were	 harvested	 from	Spleens,	
Tumour	Draining	Lymph	Nodes	(TDLN)	and	Tumours,	and	the	percentage	of	Thy1.1+	cells	was	




















from	within	 the	secondary	 lymphoid	 tissues	of	 tumour	bearing	mice,	or	 that	 their	numbers	
were	below	the	limit	of	detection.	To	determine	if	Clone	4	memory	T	cells	could	be	expanded	
ex	 vivo	 using	 specific	 antigen,	 splenocytes	were	harvested	 and	placed	 in	 culture	with	KdHA	
peptide	and	IL-2	medium,	as	this	culture	protocol	reliably	induces	expansion	of	naïve	Thy1.1+	















































































7.2.2 Does	 the	 balance	 of	 TEM	 and	 TCM	 cells	 vary	 between	 mice	 in	 which	












a	 reduced	 risk	 of	 relapse	 in	 the	 RencaHA	 tumour	 setting.	 To	 this	 end,	 the	 proportion	 of	
activated,	 naïve,	 TEM	 and	 TCM	 CD8+	 T	 cells	 within	 the	 secondary	 lymphoid	 tissues	 was	
compared	between	of	Responder	mice	 (in	which	relapse	did	not	occur)	and	Non-responder	
































in	which	 tumours	which	 experienced	 relapse	 (Non-responders	 -	NR).	A	 subset	 of	mice	was	
immunised	 with	 influenza	 A/PR/8/H1N1	 as	 indicated.	 Cells	 were	 stained	 with	 antibodies	
against	CD62L,	CD69	and	CD44.	Pie	charts	show	proportion	of	TEM,	TCM,	naïve	and	effector	
cells.	 N	 =	 23	 mice	 analysed	 over	 7	 experiments.	 Proportion	 of	 cells	 in	 each	 segment	 was	











i. Spleen  










iii – TDLN  
iv – TDLN (Immunised)  
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7.2.4 Does	 A2aR	 and	 anti-TIM3mAb	 engagement	 affect	 the	 TCR	 signalling	
required	to	generate	a	memory	T	cell	response?		





















localise	 to	 the	 immune	 synapse,	 Clone	 4	 CTL	 were	 cultured	 in	 the	 presence	 of	 the	 pan-
adenosine	 receptor	 agonist	 NECA.	 NECA-treated	 CTL	 were	 then	 imaged	 during	 cell-couple	
formation	with	Renca	tumour	cell	targets.	Several	studies	have	shown	that	PKCq	 localises	to	
the	central	area	of	immune	synapse	to	exert	its	signal	transduction,	therefore	central	patterns	
of	 PKCq	 accumulation	were	 compared	 between	NECA-treated	CTL	 and	untreated	CTL	 (47).	
Overall,	the	data	showed	that	an	initial	peak	of	central	PKCθ	accumulation	occurred	at	the	CTL	
immune	synapse.	This	peak	was	delayed	but	greater	in	magnitude	amongst	NECA-treated	CTL	









As	 the	 localisation	 of	 PKCq	 was	 affected	 by	 adenosine	 receptor	 signalling	 in	 vitro,	 it	 was	
concluded	that	systemic	blockade	of	A2aRs	in	vivo	could	affect	the	localisation	of	PKCq	amongst	
Clone	 4	 TILs,	 and	 this	 could	 improve	 the	 potential	 for	 TILs	 to	 form	 anti-tumour	 immune	
memory	cells.	Experiments	to	determine	if	this	is	the	case	could	involve	adoptive	transfer	of	
PKCqGFP-expressing	 Clone	 4	 CTL	 into	 tumour-bearing	 mice	 receiving	 systemic	 blockade	 of	
A2aRs.	PKCqGFP-expressing	Clone	4	TILs	could	then	be	recovered,	and	the	localisation	of	PKCq	
at	 the	 immune	 synapse	 could	 be	 quantified	 amongst	 TILs	 using	 live	 cell	 imaging	 ex	 vivo.	
However,	Clone	4	T	cell	populations	do	not	 take	up	the	PKCqGFP	construct	efficiently	during	






staining	 on	 a	 coverslip	 could	 then	 be	 used	 to	 identify	 the	 location	 of	 PKCq	 at	 the	 immune	
































































eradicate	 existing	 tumour	 lesions.	 However,	 the	 ability	 of	 ATT	 cells	 to	 form	 anti-tumour	
immune	memory	populations	 is	 not	 clear	 (218,	 259).	 In	 fact,	 T	 cells	 used	 for	ATT	 typically	
respond	to	tumour	antigen	with	high	affinity,	and	studies	have	shown	that	T	cell	clones	with	





sustained	 tumour	 regression	 (Responders).	Responder	mice	were	able	 to	 resist	 rechallenge	
with	 further	 injections	of	 tumour	cells,	 suggesting	 that	 they	possessed	anti-tumour	 immune	
memory	(226,	228,	264).	As	Thy1.1+	ATT	Clone	4	T	cells	respond	to	HA	antigen	with	such	high	
affinity,	 we	 hypothesised	 that	 they	 would	 not	 differentiate	 into	 memory	 T	 cells,	 and	 that	
immune	memory	to	RencaHA	tumours	would	be	mediated	by	the	host’s	endogenous	Thy1.2+	




























As	 an	 alternative	 strategy	 to	 determine	 if	memory	 T	 cells	 derived	 from	Clone	 4	 TILs	were	
required	 to	 prevent	 tumour	 relapse,	 depletion	 of	 Thy1.1+	 cells	 in	 Responder	 mice	 was	
performed	after	tumour	regression.	Tumours	relapsed	after	depletion,	indicating	that	memory	
cells	derived	 from	Clone	4	TILs	were	actively	preventing	 relapse.	Tumour	 relapse	occurred	
faster	if	endogenous	CD8+	memory	T	cells	were	depleted	as	well	as	Clone	4	populations.	This	
finding	suggests	that	populations	of	both	endogenous	CD8+	TILs	and	adoptively	transferred	







could	 not	 be	 statistically	 compared	 between	 Thy1.1-depleted	 and	 pan-CD8-depleted	 mice.	







proportion	 of	 endogenous	 CD8+	 TILs	 produce	 effector	 cytokines,	 and	 fewer	 produce	 IL-10	









cells.	 It	 is	 not	 clear	 whether	 or	 not	 the	 presence	 of	 elevated	 numbers	 of	 either	 subset	 is	
associated	with	prevention	of	tumour	relapse.	TCM	cells	may	be	advantageous	because	they	
can	 home-to	 and	 persist	 within	 secondary	 lymphoid	 tissues,	 enabling	 them	 to	 propagate	






We	 postulated	 that	 by	 identifying	 differences	 in	 the	memory	 T	 cell	 subsets	 present	within	








(TRM)	 cells.	 However,	 processing	 of	 the	 epidermis	 and	 dermis	 of	 the	 dorsal	 neck	 did	 not	






cells	 could	 be	 responding	 to	 tumour	 antigen	 in	 the	 periphery	 rather	 than	 residing	 in	 the	
secondary	 lymphoid	 tissues.	 This	 would	 not	 occur	 in	 Responders	 because	 they	 don’t	 have	
remaining	tumour	tissue.		
	
However,	 Responder	mice	 in	 Group	 D	 (ATT	 +	 anti-TIM3mAb),	which	 did	 not	 have	 tumour	
tissue,	 also	 had	 low	 numbers	 of	 TEM	 cells	 in	 the	 spleen,	 at	 a	 level	 which	 resembled	 Non-
responders.	Group	D	mice	had	the	highest	risk	of	relapse	of	any	treatment	group.	This	led	us	to	
suggest	 that	 the	presence	of	TEM	cells	 in	the	spleen	was	different	between	Responders	and	






















7.3.3 A	 loss	 of	 CD8+TEM	 cells	 from	 the	 secondary	 lymphoid	 tissues	 after	
immunisation,	is	associated	with	a	reduced	risk	of	tumour	Relapse		
Following	 immunisation	with	 influenza	 virus	 A/PR/8,	 the	 number	 of	 TEM	 cells	 within	 the	
spleen	and	TDLN	of	Responders	reduced	dramatically,	whereas	in	Non-Responders,	TEM	cell	
numbers	 remained	 the	 same.	 In	 Responders,	 the	 fact	 that	 immunisation	 with	 HA	 antigen	
induced	a	loss	of	TEM	cells	could	indicate	that	they	diverted	to	a	TCM	phenotype.	Alternatively,	
the	 TEM	 pool	 within	 responders	 could	 have	 mobilised	 from	 the	 lymphoid	 tissues	 to	 the	
peripheral	site	of	influenza	antigen.	The	latter	explanation	is	more	likely,	since	studies	suggest	
















A	 further	 interesting	 observation	 from	 the	 above	 experiments	 is	 that	 anti-tumour	 immune	
memory	appears	 to	be	HA-specific	 in	 the	RencaHA	model.	Depletion	 experiments	 show	 the	
importance	of	HA-specific	Thy1.1+	Clone	4	T	cells	in	preventing	relapse,	and	immunisation	with	

















be	 enhanced	 by	 blocking	 TIM3	 and	 A2aRs	 (Chapter	 5,	 Figure	 37).	 A2aR	 engagement	 could	
inhibit	Rho	GTPases	required	for	migration,	and	suppress	endothelial	activation,	explaining	this	
finding.	The	ability	of	TEM	cells	to	migrate	from	the	secondary	lymphoid	tissues	to	the	site	of	
influenza	 injection	 could	 be	 influenced	 by	 A2aRs	 in	 the	 same	 way.	 The	 effects	 of	 TIM3	
engagement	on	T	cell	migratory	pathways	have	not	been	studied	however,	TIM3	could	affect	
the	propensity	of	clones	of	CD8+	TILs	to	differentiate	into	T	effector	memory	cells.	One	study	
has	 indicated	 that	 TIM3	 signalling	 directly	 promotes	 short	 lived	 effector	 cell	 fates	 amongst	
CD8+	T	cells,	and	inhibits	memory	formation	during	LCMV	infection	(256).		
	
To	 determine	 whether	 A2aR	 and	 TIM3	 engagement	 directly	 inhibited	 memory	 T	 cell	


















PKCq	 localisation	 could	 involve	 the	use	of	 the	RencaHA	spheroid	 system	 (Chapter	6,	 6.3.5).	
PKCqGFP-expressing	Clone	4	CTL	could	be	allowed	to	infiltrate	spheroids,	and	live	cell	imaging	
of	SILs	could	be	used	to	determine	the	localisation	of	PKCqGFP	when	Clone	4	SILs	form	immune	
synapses	 after	 recovery	 from	 the	 spheroid.	 This	 experiment	 would	 determine	 whether	
exposure	to	a	microenvironment	of	RencaHA	cells,	with	no	other	factors	in	the	organoid,	affects	





determine	 whether	 engagement	 of	 TIM3	 and	 A2aRs	 causes	 suppression	 of	 memory	 TCR	
signalling	within	the	spheroid	microenvironment.		
	
Priming	 events	 are	 important	 in	 determining	 T	 cell	 fates	 including	 memory,	 therefore	 the	
localisation	of	PI3K,	NFkB	and	PKCq	should	be	also	be	examined	during	priming	of	naïve	Clone	
4	 T	 cells	 at	 the	 TDLN.	 The	 use	 of	 live	 cell	 imaging	 assays	 only	 assesses	 the	 localisation	 of	


























identifying	7	 crucial	 stages	 in	 the	 anti-tumour	 immune	 response.	 If	 any	 of	 these	 stages	 are	
inhibited,	 cancers	 can	 escape	 immune	 destruction	 (174).	 Although	 the	 result	 of	 the	 Cancer	


















which	have	 infiltrated	 the	 tumour,	and	 inhibiting	Treg	development	and	 function.	However,	
this	 combination	 of	 blocking	 mAb	 does	 not	 target	 tumour	 infiltration	 or	 the	 steps	 which	















of	 tumours	 by	 primed	 CD8+	 T	 cells.	 Thus	 there	 are	 three	 key	 levels	 at	which	 CD8+	 T	 cell-
mediated	anti-cancer	immunity	is	inhibited,	priming,	infiltration	and	killing	(174).	Depending	
on	the	tumour	type,	different	stages	of	the	cycle	are	inhibited,	and	immunotherapy	should	aim	




























the	 tumour	 (102,	 119).	 This	 may	 occur	 because	 cancers	 downregulate	 surface	 antigens	
required	 for	 the	anti-tumour	 immune	response,	or	because	cancer	 cell	death	as	a	 source	of	
antigen	 is	 occurring	 at	 low	 levels	 (102,	 119,	 312).	 Combining	 targeted	 therapy	 with	
immunotherapy	 can	 be	 an	 effective	 strategy	 to	 engender	 cancer	 cell	 death	 as	 a	 source	 of	
antigen,	 for	 example,	 the	use	of	Focal	Adhesion	Kinase	 (FAK)	 inhibitors	has	been	 shown	 to	






Most	 tumours	 fall	 into	 two	 intermediate	 categories	 of	 immunoscore	 known	 as	 Altered-
Immunosuppressed	or	Altered-Excluded	(119).	There	is	often	much	overlap	between	tumours	
in	these	categories	and	many	cancers	are	found	to	possess	characteristics	of	both	intermediate	
immunoscores	 (102,	 119,	 306).	 In	 these	 categories,	 cancer	 cells	 typically	 express	 tumour-
specific	 or	 tumour-associated	 antigens,	 and	 CD8+	 TIL	 priming	 and	 infiltration	 do	 occur.	
However,	 the	 processes	 of	 priming	 and	 infiltration	 are	 inhibited	 by	 the	 presence	 of	
immunosuppressive	 factors	within	 the	TME	 (102,	119,	174,	308).	Hypoxia,	 small	molecules	




DC	maturation,	 antigen	 presentation	 and	 lymphocyte	migration	 (44,	 311,	 313).	 Commonly,	
infiltration	of	TILs	is	only	partial,	reaching	only	the	peripheral	regions	of	the	tumour	mass,	and	
any	CD8+	TILs	which	do	successfully	infiltrate	the	tumour	are	quickly	suppressed	by	the	same	





















Altered-Excluded	 and	 Altered-Immunosuppressed	 immunoscores	 are	 assigned	 to	 tumours	
which	have	CD8+TILs	(here,	labelled	CT	cells).	However,	in	Excluded	and	Immunosuppressed	
tumours,	a	complex	combination	of	immunosuppressive	(IM)	immune	cells	and	soluble	factors	
synergise	 with	 co-inhibitory	 receptor	 expression	 to	 suppress	 CD8+	 TIL	 cytotoxic	 function.	
Hence	 improving	 the	 priming	 and	 infiltration	 of	 CD8+	 TILs	 into	 Immunosuppressed	 or	
Excluded	tumours	is	beneficial,	to	change	the	quality	of	the	infiltrate	towards	an	inflammatory,	
anti-tumour	 type	 (119).	 Excluded	 tumours	 are	 differentiated	 from	 immunosuppressed	
tumours,	because	they	have	fewer	CD8+	TILs	,		
	




































Currently,	 studies	 suggest	 that	 Anti-CTLA-4	 and	 Anti-PD-1	 mAbs	 are	 most	 effective	 in	 the	
treatment	of	Hot	tumours,	and	that	they	only	improve	CD8+	TIL	effector	function	within	the	
TME,	 without	 improving	 CD8+	 TIL	 priming	 or	 infiltration.	 Therefore	 developing	





Another	 limitation	 of	 current	 anti-cancer	 immunotherapies	 is	 immune-mediated	 toxicity.	













be	 potently	 immunosuppressive,	 and	 which	 could	 be	 blocked	 for	 immunotherapy	 (119).	
Previous	 studies	 showed	 that	 CD4+Tregs	 and	MDSC	within	 the	 RencaHA	 TME	 express	 the	
adenosine	producing	enzymes	CD39	and	CD73,	 and	 that	RencaHA	 tumour-infiltrating	CD4+	
Tregs	suppressed	naïve	CD8+	T	cells	ex	vivo	in	an	A2a	adenosine	receptor	(A2aR)	dependent	
manner	(154).	Other	studies	suggested	that	blocking	immunosuppressive	A2aRs	or	adenosine	











tumour	 growth	 (119).	 Blockade	 of	 A2a	 Adenosine	 Receptors	 produced	 partial	 control	 of	






















regression,	 because	 another	 immunosuppressive	 pathway	 was	 restraining	 the	 cytotoxic	
effector	 function	of	CD8+	TILs	 in	our	model,	 allowing	RencaHA	 tumours	 to	 escape	 immune	
control.	Other	studies	have	also	shown	that	when	immunotherapy	is	used	to	alleviate	one	axis	
of	suppression	within	the	TME,	the	upregulation	of	other	immunosuppressive	pathways	occurs.	








Principal	 Component	Analyses	 of	 flow	 cytometric	 data	 indicated	 that	 expression	 of	 the	 CIR	





Therefore,	 we	 hypothesised	 that	 TIM3	 blockade	 could	 synergise	 with	 A2aR	 blockade	 to	
improve	CD8+	TIL	effector	function	within	the	TME.	Although	the	percentage	expression	of	PD-
1	and	TIGIT	was	also	elevated	amongst	TILs	 from	RencaHA	 tumours	which	 received	A2aR-
Antagonist,	these	two	CIRs	are	known	to	be	involved	in	peripheral	tolerance,	so	they	were	not	
targeted	for	therapy	(117,	120).	TIM3,	has	been	shown	to	be	overexpressed	amongst	TILs	when	





In	 blocking	 TIM3	 and	 A2aRs	 in	 combination,	we	 identified	 an	 immunotherapeutic	 strategy	
which	 targets	 two	 axes	 of	 immunosuppression	 found	 within	 Altered-
















The	 RencaHA	 model	 utilises	 HA	 as	 a	 model	 tumour-specific	 antigen,	 so	 that	 ATT	 of	 TCR-
transgenic	HA-specific	 Clone	4	 CD8+	T	 cells	 can	 be	 used	 to	 replicate	 human	T	 cell	 transfer	
therapies.	We	hypothesised	that	combining	both	A2aR-Antagonist	and	anti-TIM3mAb	therapy	
with	ATT	of	Thy1.1+	Clone	4	T	cells	would	preserve	the	cytotoxic	effector	function	of	Clone	4	




8.6 Treating	RencaHA	 tumours	with	ATT,	 A2aR-Antagonist	 and	 anti-TIM3mAb	
restored	immune	function	at	multiple	stages	of	the	Cancer-Immunity	Cycle	
8.6.1 Improving	Killing	of	Tumour	Cells	by	CD8+	TILs	












treated	 tumours	 demonstrated	 improved	 killing	when	 compared	with	 TILs	 from	 untreated	





treated	 tumours,	when	 compared	with	TILs	 from	untreated	 tumours,	 and	 immune	 synapse	
stability	was	restored	to	the	levels	observed	amongst	in	vitro	primed	Clone	4	CTL	(48,	71,	76).	
We	 have	 previously	 shown	 that	 blockade	 of	 PD-1	 in	 RencaHA	 tumours	 can	 also	 improve	
morphological	measures	of	immune	synapse	stability	amongst	TILs,	therefore	immunotherapy	
is	known	to	modulate	this	process.	Together	tumour	growth	data	and	ex	vivo	analyses	support	





















Hence,	 as	 well	 as	 directly	 improving	 the	 killing	 function	 of	 ATT	 cells,	 administering	 A2aR	
antagonist	and	anti-TIM3mAb	may	also	improve	the	ability	of	Clone	4	TILs	to	produce	effector	
cytokines	such	as	IFNg.	Further	work	could	use	intracellular	cytokine	staining	to	compare	IFNg	








A2aRs	 and	 TIM3	 does	 indeed	 improve	 priming	 of	 endogenous	 CD8+	 TILs.	 Depletion	
experiments	 using	 specific	mAb	 could	 be	 	 utilised	 to	 establish	whether	 an	 improvement	 in	
priming	of	endogenous	TILs	depended	on	IFNg	produced	by	ATT	Clone	4	TILs.		
	
8.6.3 Improving	 the	 number	 of	 CD8+	 TILs	 and	 reducing	 the	 number	 of	 T	
Regulatory	cells	within	the	TME		












TIM3	 on	 infiltration	 is	 not	 well	 understood,	 however	 in	 later	 experiments,	 the	 ability	 of	 T	

















One	 key	 aim	 of	 cancer	 immunotherapy	 is	 to	 generate	 populations	 of	 anti-tumour	 immune	
memory	cells	which	could	be	activated	to	eradicate	minimal	residual	disease	in	cancer	patients	
(230,	323).	Amongst	RencaHA	tumour-bearing	mice	treated	with	combinations	of	ATT,	A2aR-














amongst	Non-responders.	Therefore,	 a	 functional	 and	mobile	 secondary	TEM	response	was	
associated	 with	 resistance	 to	 relapse	 in	 the	 RencaHA	 model.	 Depletion	 experiments	 using	
specific	mAbs	indicated	that	memory	cells	derived	from	both	adoptively	transferred	Clone	4	




Clone	 4	 CD8+	 TILs	 to	 acquire	 a	memory	 fate,	 live	 cell	 imaging	was	 used	 to	 determine	 the	







8.6.5	 Overall	 benefits	 of	 using	 ATT,	 A2aR-Antagonist	 and	 anti-TIM3mAb	 as	
Combination	Immunotherapy	
Overall,	 the	 data	 provide	 compelling	 pre-clinical	 evidence	 that	 targeting	 A2aRs	 and	 TIM3	
concurrently	with	cell-based	therapies	can	produce	durable	tumour	regression	in	the	RencaHA	
model.	Tumour	regression	 is	 faster,	 lasts	 longer,	and	occurs	 in	more	 individuals	when	anti-
TIM3mAb	and	A2aR-Antagonist	are	administered	with	ATT,	when	compared	with	ATT	alone.	






Furthermore,	we	perceived	no	evidence	of	 autoimmune	 toxicity	 amongst	mice	 treated	with	
A2aR	and	TIM3-blockade,	 and	published	data	 suggests	 that	off-target	 effects	 are	 rare	when	
A2aR-antagonist	or	anti-TIM3mAb	are	administered	to	individuals	(116,	120,	181,	183,	184,	
325).	 Levels	of	 adenosine	within	 the	 tumour	are	up	 to	100-fold	higher	 than	 those	detected	
Discussion	
	 296	
during	 inflammation	 (191,	 194,	 268).	 Similarly,	 TIM3	 expression	 is	 30-fold	 higher	 amongst	
tumour	 infiltrating	 lymphocytes	 (TILs)	 than	amongst	PBMC	taken	 from	the	same	 individual	



































future,	 the	 analyses	 of	 Clone	 4	 CTL-target	 cell	 couples	 could	 be	 executed	 using	 an	





cultures	would	 allow	 us	 to	 determine	whether	 A2aR	 and	 TIM3	 signalling,	 as	well	 as	 other	
pathways	such	as	PGE2	and	PD-1	engagement,	regulate	Lck	at	the	CD8+	T	cell	immune	synapse.	
If	 Lck	 represents	 one	 molecule	 which	 co-ordinates	 the	 effects	 of	 several	 upstream	
immunosuppressive	pathways,	ensuring	the	function	of	Lck	within	CD8+	TILs	could	prevent	
them	 from	 being	 suppressed	 by	 several	 axes	 of	 immunosuppression	 within	 the	 tumour,	
representing	 a	 new	 and	 effective	 option	 for	 cancer-immunotherapy.	 However,	 since	 Lck	 is	
expressed	 in	 T	 cells	 body-wide,	manipulation	 of	 Lck	 could	 cause	 autoimmune	 toxicity.	 One	








Lck	 is	present	within	CD8+	T	 cells	 in	 three	main	phosphorylated	 forms,	 and	 the	balance	of	
availability	 of	 these	 phosphotypes	 affects	 the	 potential	 for	 successful	 TCR	 signalling.	
Engagement	of	the	A2aR,	a	G-protein	coupled	receptor,	mediates	an	increase	in	intracellular	
cyclic	AMP,	increasing	the	activity	of	PKA,	and	subsequently	Csk	-	a	tyrosine	kinase	which	adds	




the	TIM3	cytoplasmic	 tail	and	with	 it	 removes	a	pool	of	Lck,	 reducing	 the	potential	 for	TCR	
signal	amplification	(54,	138).	Therefore,	A2aR	signalling	and	TIM3	signalling	could	synergise	











































































































































effect	 of	 A2aR	 engagement	 on	 these	 molecules	 during	 lymphocyte	 migration	 and	 immune	
synapse	 formation	 has	 not	 been	 examined.	 Transfecting	 Clone	 4	 T	 cells	 with	 RhoA-GFP	 or	
CDC42-GFP	would	allow	the	 localisation	of	 these	GFP-conjugated	molecules	to	be	compared	












8.7.1.3 Does	 A2aR	 signalling	 induce	 IL-27-mediated	 upregulation	 of	 co-inhibitory	
receptors	in	CD8+	T	cells?	
A	recent	study	has	established	IL-27	as	a	master	controller	of	CIR	gene	expression	in	CD8+	T	
cells	 (121).	 Elevated	 cAMP	 has	 been	 shown	 to	 promote	 IL-27	 transcription	 through	 the	
transcription	 factor	 CREB	 (150,	 208).	 A2aR	 signalling	 is	 known	 to	 result	 in	 elevated	 cAMP	
within	T	cells,	however	a	conclusive	link	between	cAMP	derived	from	A2aR	engagement,	and	
IL-27	release	with	subsequent	CIR	expression	has	not	been	shown	(Figure	63)(121,	135,	137,	











to	 add	 the	 inhibitory	 Y505	 phosphorylation	 to	 Lck,	 inhibiting	 TCR	 signalling,	 however	 the	
effects	 of	 A2aR	 engagement	 on	 Lck	 phosphotype	 have	 not	 been	 conclusively	 demonstrated	
(204,	209,	210).		
	


















































The	 observation	 that	 CIR	 expression	 amongst	 TILs	 was	 reduced	 in	 A2aR-blocked	 tumours	
contradicts	our	principal	component	analysis	data,	which	suggests	that	blockade	of	A2aRs	in	

















characteristically	 observed	 only	 in	 the	 immunosuppressive	 TME	 (121).	 Therefore,	 the	
downstream	 effects	 of	 IL-27	 signalling	 are	 most	 frequently	 observed	 in	 the	 context	 of	 an	
immunosuppressive	niche,	and	not	in	vitro.	IL-27	receptor	expression	may	only	be	induced	in	
the	 presence	 of	 tumour-derived	 factors,	 and	 IL-27R	 expression	may	 represent	 one	 level	 of	
control	that	determines	the	propensity	of	T	cells	to	upregulate	different	combinations	of	CIRs	










of	 cancers,	 suggesting	 that	 A2aRs	 and	 TIM3	 are	 widely	 expressed	 in	 human	 tumours	 that	












determine	 the	 efficacy	 of	 immunotherapy	 is	 that	 xenograft	models	 involve	 the	 injection	 of	
tumour	cells	derived	from	human	cancer	patients	into	immunodeficient	mice	so	that	mice	do	










disease.	 The	 ability	 of	 A2aR-antagonists	 to	 cross	 the	 blood	 brain	 barrier	 could	make	 them	












effective	way	 to	manipulate	 several	 stages	of	 the	Cancer	 Immunity	Cycle,	 ensuring	 that	 the	
priming,	 infiltration	 and	 function	 of	 tumour-specific	 CD8+	 T	 cells	 proceeds	 effectively.	 The	
result	of	this	is	CD8+	TIL-mediated	destruction	of	tumour	cells,	and	increased	immunogenicity	
within	the	TME.	We	devised	a	combination	of	therapies	which	should	target	multiple	stages	of	
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similar	 size.	 Therefore,	 the	 number	 or	 area	 of	 apoptotic	 Renca	 tumour	 cells	 could	 not	 be	
determined.		
	
To	enable	green	CTL	 	 fluorescence	to	be	distinguished	from	green	tumour	cell	 fluorescence,	







gene,	 such	 that	 they	 produced	 red	 fluorescence	 over	 the	 entire	 cytoplasmic	 area	 (Lorena	







Clone	 4	 CTL	were	 plated	 onto	 a	monolayer	 of	 KdHA	 pulsed	Renca	 tumour	 target	 cells	 and	
imaged	using	the	Incucyte	Zoom™	live	cell	analysis	system.	(A)	Renca	cells	were	incubated	with	






(RencamCherryWT)	 and	 were	 pulsed	 with	 KdHA	 peptide	 and	 plated	 at	 various	 densities	 as	
indicated.	 A	 density	 of	 10-15	 x	 103	 cells/well,	 prepared	 4	 hours	 before	 analysis	 provided	
optimum	confluence	to	assess	tumour	cell	killing	over	the	 following	10	hours,	since	tumour	
cells	had	space	to	expand,	but	the	starting	confluence	was	also	sufficient	for	contraction	to	be	










































































RencaMCherryHA	 tumours	 were	 harvested	 from	 BALB/c	 mice	 and	 digested	 using	 enzymes.	
Tumour	cells	were	stained	using	antibodies	specific	to	CD45,	ICAM-1,	Galectin-9	and	Ceacam-1	
and	 analysed	 using	 flow	 cytometry.	 (A)	 The	 sample	 was	 gated	 to	 select	 live,	 mCherry+	
































































flow	 cytometry.	 Each	combination	 represents	 one	 of	 154	 variables	entered	 into	Principal	
Component	Analysis	(PCA),	along	with	tumour	volume.		(A)	Each	dot	represents	an	individual	



















































































































Clone	4	CTL	were	primed	 in	 vitro.	RencaHA	or	RencaHAPDL1-/-	 tumour	bearing	BALB/c	mice	
were	given	Clone	4	ATT	and	treated	with	either	anti-PD-1	mAb	or	isotype	control.	Clone	4	TILs	
were	harvested	 and	 (A)	patterns	of	 F-tractin	 accumulation	were	quantified	during	 immune	
synapse	 formation	 using	 confocal	 imaging	 or	 (C)	 TILs	 were	 harvested	 and	 placed	 in	 a	
microscopic	cytotoxicity	assay.	Alternatively,	RencaHA	tumour-bearing	mice	were	given	Clone	
4	ATT	in	the	absence	of	systemic	treatment	and	(B)	CTL	and	TILs	were	harvested	and	incubated	
with	 Anti-PD-1mAb	 for	 1h	 before	 confocal	 imaging.	 Patterns	 of	 F-tractin	 accumulation	 are	
shown	 (D)	 CTL	 and	 TILs	 were	 placed	 in	 microscopic	 cytotoxicity	 assays.	 Some	 cells	 were	






































































Clone	 4	 CTL	 were	 stained	 with	 Celltrace	 violet	 and	 cultured	 for	 72h	 in	 complete	 medium	
without	 IL-2.	 Various	 treatments	were	 added	 after	 24h	 in	 culture,	 as	 indicated.	 Cells	were	
harvested	 at	 72h	 and	 stained	 with	 antibodies	 specific	 to	 total	 Lck,	 Lck	 phosphorylated	 at	
Tyrosine	505	(inactive	Lck),	or	Lck	phosphorylated	at	Tyrosine	418	(active	Lck)(2).	Data	was	
analysed	 by	 flow	 cytometry.	 N=1	 experiment	 therefore	 no	 statistics	 were	 performed.	
Proliferation	was	calculated	by	quantifying	the	number	of	cells	which	divided	in	relation	to	a	
celltrace	 violet	 proliferation	 control,	 and	 those	 which	 reached	 the	 last	 2	 divisions	 of	 the	
population.	(A)	Cells	treated	with	1	µM	PGE2	+/-	1	µM	of	the	PGE2	EP2	receptor	antagonist	TG4-
155.	(B)	Cells	treated	with	1	µM	or	10	µM	NECA	+/-	1.25	µM	A2a	adenosine	receptor	antagonist	






















































cell	 targets.	 Immune	 synapse	 formation	 (cell	 coupling)	 was	 imaged	 every	 15s	 over	 46	




























































Thy1.1+	 Clone	 4	 T	 cells	 were	 selectively	 depleted	 within	 tumour-bearing	 BALB/c	 mice,	
monoclonal	 antibodies	 were	 tested	 to	 determine	 dose	 and	 efficacy.	 Commercial	 Anti-CD8b	
antibody	 (InVivoMAb	 Clone	 53-5.8)	was	 purchased	 from	 BioXcell.	 In-house	 Anti-CD8a	 and	
CD8b	depleting	antibodies,	 to	be	used	 in	combination,	were	generated	 from	hybridoma	cell	
lines	 (Clones	YTS156	and	YTS169).	 (A)	Preparations	of	 	 commercial	and	 in-house-prepared	
antibodies	were	added	to	in	vitro	primed	Clone	4	CTL	and	incubated	with	and	without	purified	
rabbit	complement.	Number	of	CD8+	T	cells	was	quantified	using	flow	cytometry.	At	the	dose	
used	 in	 vitro,	 commercial	 antibody	 depleted	 CD8+	 T	 cells	 more	 efficiently	 than	 in-house	
prepared	antibodies.	(B)	Dose	regimen	used	to	administer	antibodies	to	BALB/c	mice	in	vivo	


















































































































































well	of	a	96	well	plate.	Cells	were	cultured	 for	72h	 in	 the	presence	of	KdHA	pulsed	antigen	



































































































were	 analysed	 using	 flow	 cytometry.	 Gates	 to	 quantify	 the	 expression	 of	 markers	 were	
generated	using	FMO	samples.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Figure	S21	-	Flow	cytometric	gating	to	quantify	Phosphorylation	of	Lck	
Appendices	
	 xxxvi	
Spleens	and	TDLN	were	harvested	from	RencaHA	tumour	bearing	mice.	Samples	were	stained	
with	ZombieNIR	to	identify	live	cells,	and	antibodies	specific	to	CD8,	TCRb,	CD44,	CD69,	CD62L	
and	CD103a.	Data	were	gated	using	FMO	samples	to	quantify	expression	of	these	markers.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	S22	-	Flow	cytometric	gating	to	identify	Memory	T	cell	populations	
